Organic molecules for optoelectronic devices
Pure organic molecules with metalloids enhance the efficiency and stability of OLEDs by achieving high photoluminescence quantum yield and improved emission characteristics in blue, sky blue, green, or yellow spectral ranges.
Patent Information
- Application Number
- KR1020237003671
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-08-21
- Filing Date
- 2021-08-20
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2041-08-20
AI Technical Summary
Existing optoelectronic devices, particularly organic light-emitting diodes (OLEDs), face challenges in achieving high efficiency, color purity, and stability, especially in blue, sky blue, green, or yellow spectral ranges, with known metal complexes falling short in these aspects.
Development of pure organic molecules containing metalloids like B, Si, Sn, and/or Se, which exhibit emission maxima in the desired spectral ranges and have a photoluminescence quantum yield of 50% or higher, enhancing device efficiency and stability.
The new organic molecules increase the efficiency and color purity of OLEDs, providing higher stability compared to devices using traditional emitter materials.
Smart Images

Figure 112023011589777-PCT00076_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to organic molecules and their use in organic light-emitting diodes (OLEDs) and other optoelectronic devices. Specific details for implementing the invention
[0002] The objective of the present invention is to provide a molecule suitable for use in optoelectronic devices.
[0003] This objective is achieved by the present invention, which provides a new type of organic molecule.
[0004] According to the present invention, the organic molecule is a pure organic molecule, that is, it does not contain any metal ions, in contrast to metal complexes known to be used in optoelectronic devices. However, the organic molecule of the present invention includes metalloids, in particular, B, Si, Sn, Se, and / or Ge.
[0005] According to the present invention, the organic molecule exhibits an emission maxima in the blue, sky blue, green, or yellow spectral range. The organic molecule exhibits an emission maxima particularly at 420 nm to 520 nm, preferably 440 nm to 495 nm, more preferably 450 nm to 470 nm, or the organic molecule exhibits an emission maxima particularly at 490 nm to 600 nm, more preferably 510 nm to 560 nm, and even more preferably 520 nm to 540 nm. The photoluminescence quantum yield of the organic molecule according to the present invention is particularly 50% or higher. When the molecule according to the present invention is used in an optoelectronic device, e.g., an organic light-emitting diode (OLED), the efficiency or color purity of the device is increased, which is expressed as the emission full width at half maximum (FWHM) of the device. The corresponding OLED has higher stability than OLEDs with known emitter materials and similar colors.
[0006] The organic molecule according to the present invention comprises or consists of the following.
[0007] - A first chemical moiety comprising or composed of the structure of chemical formula I,
[0008]
[0009] Chemical Formula I
[0010] and
[0011] - Two second chemical moietyes comprising or composed of the structure of Chemical Formula II,
[0012]
[0013] Chemical Formula II
[0014] Here
[0015] X and Y are selected independently of each other in each case from the group consisting of B and N;
[0016] R I , R II , R III , R IV , R V , R VI , R VII , R VIII , R IX , and R X In each case, independently of one another, a binding site of a single bond connecting the first chemical moiety to the second chemical moiety, and R * Selected from a group consisting of:
[0017] R * is selected from a group consisting of doing independently of each other in each case;
[0018] Hydrogen, Deuterium, OPh(Ph = Phenyl), SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0019] C1-C5-alkyl,
[0020] Here, optionally, one or more hydrogen atoms are independently substituted with deuterium (D), CN, CF3, or F;
[0021] C1-C5-alkoxy,
[0022] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0023] C1-C5-thioalkoxy,
[0024] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0025] C2-C5-alkenyl,
[0026] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0027] C2-C5-alkynyl,
[0028] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0029] C6-C 18 -Aril,
[0030] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0031] C3-C 17 -Heteroaryl,
[0032] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0033] N(C6-C 18 -Aril)2;
[0034] N(C3-C 17 -heteroaryl)2; and
[0035] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril).
[0036] The dotted line in Chemical Formula 2 “ indicates a binding site of the first chemical moiety to the second chemical moiety;
[0037] Z is a direct bond;
[0038] o is an integer of 0 or 1 independently in each case;
[0039] p is an integer of 0 or 1 independently in each case;
[0040] R2 is selected from a group consisting of independent actions in each case, and
[0041] hydrogen,
[0042] heavy hydrogen,
[0043] N(R 5 )2,
[0044] OR 5 ,
[0045] Si(R 5 )3,
[0046] B(OR 5 )2,
[0047] OSO2R 5 ,
[0048] CF3,
[0049] CN,
[0050] F,
[0051] Br,
[0052] I,
[0053] C1-C 40 -alkyl,
[0054] This is one or more substituents R 5 Optionally replaced with,
[0055] Here, one or more non-adjacent CH2 groups are R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5)2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 Optionally substituted by;
[0056] C1-C 40 - Alkoxy,
[0057] This is one or more substituents R 5 Optionally replaced with,
[0058] Here, one or more non-adjacent CH2 groups are R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 Optionally substituted by;
[0059] C1-C 40 -Thioalkoxy,
[0060] This is one or more substituents R 5 Optionally replaced with,
[0061] Here, one or more non-adjacent CH2 groups are R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 Optionally substituted by;
[0062] C2-C 40 -Alkenil,
[0063] This is one or more substituents R 5 Optionally replaced with,
[0064] Here, one or more non-adjacent CH2 groups are R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 Optionally substituted by;
[0065] C2-C 40 -Alkinil,
[0066] This is one or more substituents R 5 Optionally replaced with,
[0067] Here, one or more non-adjacent CH2 groups are R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 Optionally substituted by;
[0068] C6-C 60 -Aril,
[0069] This is one or more substituents R 5 Optionally substituted as; and
[0070] C3-C 57 -Heteroaryl,
[0071] This is one or more substituents R 5 It is optionally replaced with.
[0072] R 5is selected from a group consisting of, independently of each other in each case, and
[0073] hydrogen,
[0074] heavy hydrogen,
[0075] N(R 6 )2,
[0076] OR 6 ,
[0077] Si(R 6 )3,
[0078] B(OR 6 )2,
[0079] OSO2R 6 ,
[0080] CF3,
[0081] CN,
[0082] F,
[0083] Br,
[0084] I,
[0085] C1-C 40 -alkyl,
[0086] This is one or more substituents R 6 Optionally replaced with,
[0087] Here, one or more non-adjacent CH2 groups are R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=O, C=S, C=Se, C=NR 6 , P(=O)(R 6 ), SO, SO2, NR 6 , O, S or CONR 6 Optionally substituted by;
[0088] C1-C 40 - Alkoxy,
[0089] This is one or more substituents R 6 Optionally replaced with,
[0090] Here, one or more non-adjacent CH2 groups are R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=O, C=S, C=Se, C=NR 6 , P(=O)(R 6 ), SO, SO2, NR 6 , O, S or CONR 6 Optionally substituted by;
[0091] C1-C 40 -Thioalkoxy,
[0092] This is one or more substituents R 6 Optionally replaced with,
[0093] Here, one or more non-adjacent CH2 groups are R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=O, C=S, C=Se, C=NR 6 , P(=O)(R 6 ), SO, SO2, NR 6 , O, S or CONR 6 Optionally substituted by;
[0094] C2-C 40 -Alkenil,
[0095] This is one or more substituents R 6 Optionally replaced with,
[0096] Here, one or more non-adjacent CH2 groups are R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=O, C=S, C=Se, C=NR 6 , P(=O)(R 6 ), SO, SO2, NR 6, O, S or CONR 6 Optionally substituted by;
[0097] C2-C 40 -Alkinil,
[0098] This is one or more substituents R 6 Optionally replaced with,
[0099] Here, one or more non-adjacent CH2 groups are R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=O, C=S, C=Se, C=NR 6 , P(=O)(R 6 ), SO, SO2, NR 6 , O, S or CONR 6 Optionally substituted by;
[0100] C6-C 60 -Aril,
[0101] This is one or more substituents R 6 Optionally replaced with; and
[0102] C3-C 57 -Heteroaryl,
[0103] This is one or more substituents R 6 It is optionally replaced with.
[0104] R 6 In each case, is selected independently from a group consisting of, and
[0105] Hydrogen, Deuterium, OPh, SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0106] C1-C5-alkyl,
[0107] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0108] C1-C5-alkoxy,
[0109] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0110] C1-C5-thioalkoxy,
[0111] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0112] C2-C5-alkenyl,
[0113] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0114] C2-C5-alkynyl,
[0115] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0116] C6-C 18 -Aril,
[0117] This is optionally substituted with one or more C1-C5-alkyl substituents;
[0118] C3-C 17 -Heteroaryl,
[0119] This is optionally substituted with one or more C1-C5-alkyl substituents;
[0120] N(C6-C 18 -Aril)2,
[0121] N(C3-C 17 -heteroaryl)2; and
[0122] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril);
[0123] Here
[0124] Adjacent group R 2 They optionally bond to each other to form an aryl or heteroaryl ring, which is optionally substituted with one or more C1-C5-alkyl substituents, deuterium, halogen, CN, or CF3, and
[0125] Exactly 2 types selected from the group consisting of X and Y are B, and exactly 2 types selected from the group consisting of X and Y are N;
[0126] R I and R II ,
[0127] R II and R III and
[0128] R IV and R V Two adjacent substituents selected from the group consisting of : are
[0129] It represents a binding site of a single bond that forms a ring by connecting a first chemical moiety to a second chemical moiety, and
[0130] R VI and R VII ,
[0131] R VII and R VIII and
[0132] R IX and R X Two adjacent substituents selected from the group consisting of : are
[0133] It represents the bonding site of a single bond that forms a ring by connecting a first chemical moiety to another second chemical moiety (e.g., the second).
[0134] The above organic molecule does not have more than two second chemical moieties.
[0135] Specific examples of organic molecules are listed below:
[0136]
[0137]
[0138] In a preferred embodiment, X is B and Y is N. In another embodiment, one X is B and one X is N.
[0139] In a preferred embodiment, o is 0 or 1; and p is 0 or 1.
[0140] In a preferred embodiment, o is 1.
[0141] In a preferred embodiment, p is 0 and o is 1.
[0142] In a more desirable embodiment, X is B, Y is N, p is 0, and o is 1.
[0143] In one implementation example, o and p are both 0.
[0144] In one embodiment of the present invention, R 2 is selected from a group consisting of those who do it independently:
[0145] hydrogen,
[0146] Me, i Pr, t Bu, CN, CF3,
[0147] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0148] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0149] Me, i Pr, t Carbazolyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0150] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0151] and N(Ph)2.
[0152] In a further embodiment of the present invention, R 2 is selected from a group consisting of those who do it independently:
[0153] hydrogen,
[0154] Me,
[0155] i Pr,
[0156] t Bu,
[0157] CN,
[0158] CF3,
[0159] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0160] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0161] Me, i Pr, t Pyrimidinyl optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph, and
[0162] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph.
[0163] In one embodiment, R 2 In each case, it is selected from a group consisting of independent actions.
[0164] Hydrogen, Deuterium, OPh, SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0165] C1-C5-alkyl,
[0166] Here, optionally, one or more hydrogen atoms are independently substituted with deuterium (D), CN, CF3, or F;
[0167] C1-C5-alkoxy,
[0168] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0169] C1-C5-thioalkoxy,
[0170] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0171] C2-C5-alkenyl,
[0172] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0173] C2-C5-alkynyl,
[0174] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0175] C6-C 18 -Aril,
[0176] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0177] C3-C 17 -Heteroaryl,
[0178] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0179] N(C6-C 18 -Aril)2,
[0180] N(C3-C 17 -heteroaryl)2; and
[0181] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril).
[0182] In one embodiment, R * is selected from a group consisting of doing independently of each other in each case:
[0183] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0184] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0185] In one embodiment, R 2 is selected from a group consisting of doing independently of each other in each case:
[0186] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0187] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0188] In a preferred embodiment, R 2 is selected from a group consisting of doing independently of each other in each case:
[0189] Hydrogen, deuterium, i Pr, and
[0190] Ph. optionally substituted with one or more Ph substituents.
[0191] R in a specific implementation example 2 It is hydrogen in each case.
[0192] In one embodiment, R * is selected from a group consisting of doing independently of each other in each case:
[0193] Hydrogen, Deuterium, Me, i Pr, tBu, SiMe3, SiPh3, and
[0194] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0195] In a preferred embodiment, R * is selected from a group consisting of doing independently of each other in each case:
[0196] Hydrogen, deuterium, i Pr and
[0197] Ph. optionally substituted with one or more Ph substituents.
[0198] In a specific implementation, R * It is hydrogen in each case.
[0199] In one embodiment, the organic molecule comprises or consists of the structures of the chemical formulas Ia and Ib:
[0200]
[0201] Chemical formula Ia Chemical formula Ib
[0202] Here, m is 0 or 1 and;
[0203] n is 0 or 1 and;
[0204] Exactly 2 types selected from the group consisting of X and Y are B, and exactly 2 types selected from the group consisting of X and Y are N.
[0205] In one embodiment, the organic molecule comprises or consists of the structures of chemical formulas Ia and Ib, where o is 1.
[0206] In one embodiment, the organic molecule comprises or consists of the structures of the chemical formulas Ia and Ib, where o is 1 and p is 0.
[0207] In one embodiment, the organic molecule comprises or consists of the structures of the chemical formulas Ia and Ib, where o is 1, p is 0, exactly one selected from m and n is 1, and exactly one selected from n and m is 0.
[0208] In one embodiment, the organic molecule comprises or is composed of the structures of the chemical formulas Ia and Ib, where R * is selected from a group consisting of doing independently of each other in each case:
[0209] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0210] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0211] In one embodiment of the present invention, the organic molecule comprises or is composed of the structures of the chemical formulas Ia and Ib, wherein R 2 is selected from a group consisting of those who do it independently:
[0212] hydrogen,
[0213] Me, i Pr, t Bu, CN, CF3,
[0214] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0215] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0216] Me, i Pr, tCarbazolyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0217] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0218] and N(Ph)2.
[0219] In a further embodiment of the present invention, the organic molecule comprises or is composed of the structures of the chemical formulas Ia and Ib, wherein R 2 is selected from a group consisting of those who do it independently:
[0220] hydrogen,
[0221] Me,
[0222] i Pr,
[0223] t Bu,
[0224] CN,
[0225] CF3,
[0226] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0227] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0228] Me, i Pr, t Pyrimidinyl optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph, and
[0229] Me, i Pr, tTriazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph.
[0230] In one embodiment, the organic molecule comprises or is composed of the structures of the chemical formulas Ia and Ib, where R 2 is selected from a group consisting of each case independently of the others:
[0231] Hydrogen, Deuterium, OPh, SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0232] C1-C5-alkyl,
[0233] Here, optionally, one or more hydrogen atoms are independently substituted with deuterium (D), CN, CF3, or F;
[0234] C1-C5-alkoxy,
[0235] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0236] C1-C5-thioalkoxy,
[0237] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0238] C2-C5-alkenyl,
[0239] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0240] C2-C5-alkynyl,
[0241] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0242] C6-C 18 -Aril,
[0243] This optionally includes one or more C1-C 5-- Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0244] C3-C 17 -Heteroaryl,
[0245] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0246] N(C6-C 18 -Aril)2,
[0247] N(C3-C 17 -heteroaryl)2; and
[0248] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril).
[0249] In one embodiment, the organic molecule comprises or is composed of the structures of the chemical formulas Ia and Ib, where R 2 In each case, it is selected from a group consisting of independent actions.
[0250] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0251] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0252] In a preferred embodiment, R 2 is selected from a group consisting of doing independently of each other in each case:
[0253] Hydrogen, deuterium, i Pr, and
[0254] Ph. optionally substituted with one or more Ph substituents.
[0255] In a specific embodiment, the organic molecule comprises or consists of the structures of the chemical formulas Ia and Ib, where R 2 It is hydrogen in each case.
[0256] In one embodiment, the organic molecule comprises or is composed of the structures of the chemical formulas Ia and Ib, where R * is selected from a group consisting of doing independently of each other in each case:
[0257] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0258] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0259] In a preferred embodiment, the organic molecule comprises or consists of the structures of the chemical formulas Ia and Ib, where R * is selected from a group consisting of doing independently of each other in each case:
[0260] Hydrogen, deuterium, i Pr and
[0261] Ph. optionally substituted with one or more Ph substituents.
[0262] In a specific embodiment, the organic molecule comprises or consists of the structures of the chemical formulas Ia and Ib, where R * It is hydrogen in each case.
[0263] In one embodiment, the organic molecule comprises or is composed of the structures of the chemical formulas Ia and Ib, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0264] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0265] Me, i Pr, tPh. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0266] In a preferred embodiment, the organic molecule comprises or consists of the structures of the chemical formulas Ia and Ib, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0267] Hydrogen, deuterium, i Pr and
[0268] Ph. optionally substituted with one or more Ph substituents.
[0269] In a specific embodiment, the organic molecule comprises or consists of the structures of the chemical formulas Ia and Ib, where R 2 , and R * It is hydrogen in each case.
[0270] In one embodiment, the organic molecule comprises or consists of the structures of chemical formulas Ia and Ib, and o, p, n and m are 0.
[0271] In one embodiment, the organic molecule comprises or consists of the structure of formula Ia:
[0272]
[0273] Chemical formula Ia
[0274] Here, exactly 2 species selected from the group consisting of X and Y are B, and exactly 2 species selected from the group consisting of X and Y are N.
[0275] In one embodiment, the organic molecule comprises or consists of the structure of formula Ia, where o is 1.
[0276] In one embodiment, the organic molecule comprises or consists of the structure of formula Ia, where o is 1, p is 0, exactly one selected from m and n is 1, and exactly one selected from n and m is 0.
[0277] In one embodiment, the organic molecule comprises or is composed of the structure of formula Ia, where R * is selected from a group consisting of doing independently of each other in each case:
[0278] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0279] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0280] In one embodiment, the organic molecule comprises or is composed of the structure of formula Ia, where R 2 is selected from a group consisting of those who do it independently:
[0281] hydrogen,
[0282] Me, i Pr, t Bu, CN, CF3,
[0283] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0284] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0285] Me, i Pr, tCarbazolyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0286] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0287] and N(Ph)2.
[0288] In a further embodiment of the present invention, the organic molecule comprises or is composed of the structure of formula Ia, wherein R 2 is selected from a group consisting of those who do it independently:
[0289] hydrogen,
[0290] Me,
[0291] i Pr,
[0292] t Bu,
[0293] CN,
[0294] CF3,
[0295] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0296] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0297] Me, i Pr, t Pyrimidinyl optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph, and
[0298] Me, i Pr, tTriazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph.
[0299] In one embodiment, the organic molecule comprises or is composed of the structure of formula Ia, where R 2 is selected from a group consisting of each case independently of the others:
[0300] Hydrogen, Deuterium, OPh, SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0301] C1-C5-alkyl,
[0302] Here, optionally, one or more hydrogen atoms are independently substituted with deuterium (D), CN, CF3, or F;
[0303] C1-C5-alkoxy,
[0304] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0305] C1-C5-thioalkoxy,
[0306] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0307] C2-C5-alkenyl,
[0308] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0309] C2-C5-alkynyl,
[0310] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0311] C6-C 18 -Aril,
[0312] This optionally includes one or more C1-C 5-- Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0313] C3-C 17 -Heteroaryl,
[0314] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0315] N(C6-C 18 -Aril)2,
[0316] N(C3-C 17 -heteroaryl)2; and
[0317] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril).
[0318] In one embodiment, the organic molecule comprises or is composed of the structure of formula Ia, where R 2 In each case, it is selected from a group consisting of independent actions.
[0319] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0320] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0321] In a preferred embodiment, the organic molecule comprises or is composed of the structure of formula Ia, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0322] Hydrogen, deuterium, i Pr, and
[0323] Ph. optionally substituted with one or more Ph substituents.
[0324] In a specific embodiment, the organic molecule comprises or is composed of the structure of formula Ia, where R 2 It is hydrogen in each case.
[0325] In one embodiment, the organic molecule comprises or is composed of the structure of formula Ia, where R * is selected from a group consisting of doing independently of each other in each case:
[0326] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0327] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0328] In a preferred embodiment, the organic molecule comprises or is composed of the structure of formula Ia, where R * is selected from a group consisting of doing independently of each other in each case:
[0329] Hydrogen, deuterium, i Pr and
[0330] Ph. optionally substituted with one or more Ph substituents.
[0331] In a specific embodiment, the organic molecule comprises or is composed of the structure of formula Ia, where R * It is hydrogen in each case.
[0332] In one embodiment, the organic molecule comprises or is composed of the structure of formula Ia, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0333] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0334] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0335] In a preferred embodiment, the organic molecule comprises or is composed of the structure of formula Ia, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0336] Hydrogen, deuterium, i Pr and
[0337] Ph. optionally substituted with one or more Ph substituents.
[0338] In a specific embodiment, the organic molecule comprises or is composed of the structure of formula Ia, where R 2 , and R * It is hydrogen in each case.
[0339] In one embodiment, the organic molecule comprises or consists of the structure of formula Ia, where o, p, n and m are 0.
[0340] In one embodiment, the organic molecule comprises or consists of the structure of the formula Ib:
[0341]
[0342] Chemical formula Ib
[0343] Here, exactly 2 species selected from the group consisting of X and Y are B, and exactly 2 species selected from the group consisting of X and Y are N.
[0344] In one embodiment, the organic molecule comprises or consists of the structure of the formula Ib, where o is 1.
[0345] In one embodiment, the organic molecule comprises or consists of the structure of the formula Ib, where o is 1, p is 0, exactly one selected from m and n is 1, and exactly one selected from n and m is 0.
[0346] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Ib, where R * is selected from a group consisting of doing independently of each other in each case:
[0347] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0348] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0349] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Ib, where R 2 is selected from a group consisting of those who do it independently:
[0350] hydrogen,
[0351] Me, i Pr, t Bu, CN, CF3,
[0352] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0353] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0354] Me, i Pr, tCarbazolyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0355] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0356] and N(Ph)2.
[0357] In a further embodiment of the present invention, the organic molecule comprises or is composed of the structure of the formula Ib, where R 2 is selected from a group consisting of those who do it independently:
[0358] hydrogen,
[0359] Me,
[0360] i Pr,
[0361] t Bu,
[0362] CN,
[0363] CF3,
[0364] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0365] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0366] Me, i Pr, t Pyrimidinyl optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph, and
[0367] Me, i Pr, tTriazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph.
[0368] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Ib, where R 2 is selected from a group consisting of each case independently of the others:
[0369] Hydrogen, Deuterium, OPh, SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0370] C1-C5-alkyl,
[0371] Here, optionally, one or more hydrogen atoms are independently substituted with deuterium (D), CN, CF3, or F;
[0372] C1-C5-alkoxy,
[0373] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0374] C1-C5-thioalkoxy,
[0375] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0376] C2-C5-alkenyl,
[0377] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0378] C2-C5-alkynyl,
[0379] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0380] C6-C 18 -Aril,
[0381] This optionally includes one or more C1-C 5-- Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0382] C3-C 17 -Heteroaryl,
[0383] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0384] N(C6-C 18 -Aril)2,
[0385] N(C3-C 17 -heteroaryl)2; and
[0386] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril).
[0387] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Ib, where R 2 In each case, it is selected from a group consisting of independent actions.
[0388] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0389] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0390] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Ib, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0391] Hydrogen, deuterium, i Pr, and
[0392] Ph. optionally substituted with one or more Ph substituents.
[0393] In a specific embodiment, the organic molecule comprises or is composed of the structure of the formula Ib, where R 2 It is hydrogen in each case.
[0394] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Ib, where R * is selected from a group consisting of doing independently of each other in each case:
[0395] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0396] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0397] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Ib, where R * is selected from a group consisting of doing independently of each other in each case:
[0398] Hydrogen, deuterium, i Pr and
[0399] Ph. optionally substituted with one or more Ph substituents.
[0400] In a specific embodiment, the organic molecule comprises or is composed of the structure of the formula Ib, where R * It is hydrogen in each case.
[0401] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Ib, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0402] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0403] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0404] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Ib, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0405] Hydrogen, deuterium, i Pr and
[0406] Ph. optionally substituted with one or more Ph substituents.
[0407] In a specific embodiment, the organic molecule comprises or is composed of the structure of the formula Ib, where R 2 , and R * It is hydrogen in each case.
[0408] In one embodiment, the organic molecule comprises or consists of the structure of the formula Ib, where o, p, n and m are 0.
[0409] In one embodiment, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties comprise one structure selected from the group consisting of Formulas IIa and IIb:
[0410]
[0411] Chemical formula IIa Chemical formula IIb
[0412] In one embodiment, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties comprise one structure selected from the group consisting of Formulas IIa and IIb, where R *is selected from a group consisting of doing independently of each other in each case:
[0413] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0414] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0415] In one embodiment, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties comprise one structure selected from the group consisting of Formulas IIa and IIb, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0416] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0417] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0418] In one embodiment of the present invention, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties comprise one structure selected from the group consisting of Formulas IIa and IIb, and R 2 is selected from a group consisting of doing independently of each other in each case:
[0419] hydrogen,
[0420] Me, i Pr, t Bu, CN, CF3,
[0421] Me, i Pr, tPh optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0422] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0423] Me, i Pr, t Carbazolyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0424] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0425] and N(Ph)2.
[0426] In one embodiment of the present invention, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties comprise one structure selected from the group consisting of Formulas IIa and IIb, and R 2 is selected from a group consisting of doing independently of each other in each case:
[0427] hydrogen,
[0428] Me,
[0429] i Pr,
[0430] t Bu,
[0431] CN,
[0432] CF3,
[0433] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0434] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0435] Me, i Pr, t Pyrimidinyl optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph, and
[0436] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph.
[0437] In one embodiment of the present invention, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties comprise one structure selected from the group consisting of Formulas IIa and IIb, and R 2 is selected from a group consisting of doing independently of each other in each case:
[0438] Hydrogen, Deuterium, OPh, SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0439] C1-C5-alkyl,
[0440] Here, optionally, one or more hydrogen atoms are independently substituted with deuterium (D), CN, CF3, or F;
[0441] C1-C5-alkoxy,
[0442] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0443] C1-C5-thioalkoxy,
[0444] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0445] C2-C5-alkenyl,
[0446] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0447] C2-C5-alkynyl,
[0448] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0449] C6-C 18 -Aril,
[0450] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0451] C3-C 17 -Heteroaryl,
[0452] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0453] N(C6-C 18 -Aril)2,
[0454] N(C3-C 17 -heteroaryl)2; and
[0455] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril).
[0456] In one embodiment of the present invention, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties comprise one structure selected from the group consisting of Formulas IIa and IIb, and R 2 is selected from a group consisting of doing independently of each other in each case:
[0457] Hydrogen, deuterium, iPr, and
[0458] Ph. optionally substituted with one or more Ph substituents.
[0459] In one embodiment of the present invention, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties comprise one structure selected from the group consisting of Formulas IIa and IIb, and R 2 It is hydrogen in each case.
[0460] In one embodiment of the present invention, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties comprise one structure selected from the group consisting of Formulas IIa and IIb, and R * is selected from a group consisting of doing independently of each other in each case:
[0461] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0462] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0463] In one embodiment of the present invention, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties comprise one structure selected from the group consisting of Formulas IIa and IIb, and R * is selected from a group consisting of doing independently of each other in each case:
[0464] Hydrogen, deuterium, i Pr and
[0465] Ph. optionally substituted with one or more Ph substituents.
[0466] In one embodiment of the present invention, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties comprise one structure selected from the group consisting of Formulas IIa and IIb, and R * It is hydrogen in each case.
[0467] In one embodiment, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties are composed of the structure of Formula IIa:
[0468]
[0469] Chemical formula IIa.
[0470] In one embodiment, the organic molecule comprises or is composed of the structure of Formula I, wherein exactly two second chemical moieties are composed of the structure of Formula IIb:
[0471]
[0472] Chemical formula IIb.
[0473] In one embodiment, the organic molecule comprises or consists of one structure of the formulas Ia-I, Ia-II, Ia-III, and Ia-IV:
[0474]
[0475] Chemical formula Ia-I Chemical formula Ia-II
[0476]
[0477] Chemical formula Ia-III Chemical formula Ia-IV
[0478] In one embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of chemical formulas Ia-I, Ia-II, Ia-III, and Ia-IV, where R * is selected from a group consisting of doing independently of each other in each case:
[0479] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0480] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0481] In one embodiment of the present invention, the organic molecule comprises or is composed of a structure selected from the group consisting of chemical formulas Ia-I, Ia-II, Ia-III, and Ia-IV, wherein R 2 is selected from a group consisting of doing independently of each other in each case:
[0482] hydrogen,
[0483] Me, i Pr, t Bu, CN, CF3,
[0484] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0485] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0486] Me, i Pr, t Carbazolyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0487] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0488] and N(Ph)2.
[0489] In a further embodiment of the present invention, the organic molecule comprises or is composed of a structure selected from the group consisting of formulas Ia-I, Ia-II, Ia-III, and Ia-IV, wherein R 2 is selected from a group consisting of doing independently of each other in each case:
[0490] hydrogen,
[0491] Me,
[0492] i Pr,
[0493] t Bu,
[0494] CN,
[0495] CF3,
[0496] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0497] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0498] Me, i Pr, t Pyrimidinyl optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph, and
[0499] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph.
[0500] In one embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of chemical formulas Ia-I, Ia-II, Ia-III, and Ia-IV, where R2 is selected from a group consisting of doing independently of each other in each case:
[0501] Hydrogen, Deuterium, OPh, SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0502] C1-C5-alkyl,
[0503] Here, optionally, one or more hydrogen atoms are independently substituted with deuterium (D), CN, CF3, or F;
[0504] C1-C5-alkoxy,
[0505] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0506] C1-C5-thioalkoxy,
[0507] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0508] C2-C5-alkenyl,
[0509] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0510] C2-C5-alkynyl,
[0511] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0512] C6-C 18 -Aril,
[0513] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0514] C3-C 17 -Heteroaryl,
[0515] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0516] N(C6-C 18 -Aril)2,
[0517] N(C3-C 17 -heteroaryl)2; and
[0518] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril).
[0519] In one embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of chemical formulas Ia-I, Ia-II, Ia-III, and Ia-IV, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0520] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0521] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0522] In a preferred embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of chemical formulas Ia-I, Ia-II, Ia-III, and Ia-IV, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0523] Hydrogen, deuterium, i Pr, and
[0524] Ph. optionally substituted with one or more Ph substituents.
[0525] In a specific embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of chemical formulas Ia-I, Ia-II, Ia-III, and Ia-IV, where R 2 It is hydrogen in each case.
[0526] In one embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of chemical formulas Ia-I, Ia-II, Ia-III, and Ia-IV, where R * is selected from a group consisting of doing independently of each other in each case:
[0527] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0528] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0529] In a preferred embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of chemical formulas Ia-I, Ia-II, Ia-III, and Ia-IV, where R * is selected from a group consisting of doing independently of each other in each case:
[0530] Hydrogen, deuterium, i Pr, and
[0531] Ph. optionally substituted with one or more Ph substituents.
[0532] In a specific embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of chemical formulas Ia-I, Ia-II, Ia-III, and Ia-IV, where R * It is hydrogen in each case.
[0533] In one embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of chemical formulas Ia-I, Ia-II, Ia-III, and Ia-IV, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0534] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0535] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0536] In a preferred embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of chemical formulas Ia-I, Ia-II, Ia-III, and Ia-IV, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0537] Hydrogen, deuterium, i Pr and
[0538] Ph. optionally substituted with one or more Ph substituents.
[0539] In a specific embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of chemical formulas Ia-I, Ia-II, Ia-III, and Ia-IV, where R 2 , and R * It is hydrogen in each case.
[0540] In one embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of the chemical formulas Ib-I, Ib-II, Ib-III, and Ib-IV:
[0541]
[0542] Chemical formula Ib-I Chemical formula Ib-II
[0543]
[0544] Chemical formula Ib-III Chemical formula Ib-IV
[0545] In one embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of the formulas Ib-I, Ib-II, Ib-III, and Ib-IV, where R * is selected from a group consisting of doing independently of each other in each case:
[0546] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0547] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0548] In one embodiment of the present invention, the organic molecule comprises or is composed of a structure selected from the group consisting of the formulas Ib-I, Ib-II, Ib-III, and Ib-IV, wherein R 2 is selected from a group consisting of doing independently of each other in each case:
[0549] hydrogen,
[0550] Me, i Pr, t Bu, CN, CF3,
[0551] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0552] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0553] Me, i Pr, t Carbazolyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0554] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0555] and N(Ph)2.
[0556] In a further embodiment of the present invention, the organic molecule comprises or is composed of a structure selected from the group consisting of the formulas Ib-I, Ib-II, Ib-III, and Ib-IV, wherein R 2 is selected from a group consisting of doing independently of each other in each case:
[0557] hydrogen,
[0558] Me,
[0559] i Pr,
[0560] t Bu,
[0561] CN,
[0562] CF3,
[0563] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0564] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0565] Me, i Pr, t Pyrimidinyl optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph, and
[0566] Me, i Pr, tTriazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph.
[0567] In one embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of the formulas Ib-I, Ib-II, Ib-III, and Ib-IV, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0568] Hydrogen, Deuterium, OPh, SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0569] C1-C5-alkyl,
[0570] Here, optionally, one or more hydrogen atoms are independently substituted with deuterium (D), CN, CF3, or F;
[0571] C1-C5-alkoxy,
[0572] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0573] C1-C5-thioalkoxy,
[0574] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0575] C2-C5-alkenyl,
[0576] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0577] C2-C5-alkynyl,
[0578] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0579] C6-C 18 -Aril,
[0580] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0581] C3-C 17 -Heteroaryl,
[0582] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0583] N(C6-C 18 -Aril)2,
[0584] N(C3-C 17 -heteroaryl)2; and
[0585] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril).
[0586] In one embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of the formulas Ib-I, Ib-II, Ib-III, and Ib-IV, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0587] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0588] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0589] In a preferred embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of the formulas Ib-I, Ib-II, Ib-III, and Ib-IV, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0590] Hydrogen, deuterium, i Pr, and
[0591] Ph. optionally substituted with one or more Ph substituents.
[0592] In a specific embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of the chemical formulas Ib-I, Ib-II, Ib-III, and Ib-IV, where R 2 It is hydrogen in each case.
[0593] In one embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of the formulas Ib-I, Ib-II, Ib-III, and Ib-IV, where R * is selected from a group consisting of doing independently of each other in each case:
[0594] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0595] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0596] In one embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of the formulas Ib-I, Ib-II, Ib-III, and Ib-IV, where R * is selected from a group consisting of doing independently of each other in each case:
[0597] Hydrogen, deuterium, i Pr, and
[0598] Ph. optionally substituted with one or more Ph substituents.
[0599] In a specific embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of the formulas Ib-I, Ib-II, Ib-III, and Ib-IV, where R * It is hydrogen in each case.
[0600] In one embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of the formulas Ib-I, Ib-II, Ib-III, and Ib-IV, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0601] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0602] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0603] In a preferred embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of the formulas Ib-I, Ib-II, Ib-III, and Ib-IV, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0604] Hydrogen, deuterium, i Pr and
[0605] Ph. optionally substituted with one or more Ph substituents.
[0606] In a specific embodiment, the organic molecule comprises or is composed of a structure selected from the group consisting of the chemical formulas Ib-I, Ib-II, Ib-III, and Ib-IV, where R 2 , and R * It is hydrogen in each case.
[0607] In one embodiment, the organic molecule comprises or consists of the structure of the formula Iaa:
[0608]
[0609] Chemical formula Iaa,
[0610] Here, R Z is a single bond binding site that connects the first chemical moiety to the second chemical moiety of chemical formula IIa.
[0611] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iaa, where R * is selected from a group consisting of doing independently of each other in each case:
[0612] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0613] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0614] In one embodiment of the present invention, the organic molecule comprises or is composed of the structure of the formula Iaa, wherein R 2 is selected from a group consisting of doing independently of each other in each case:
[0615] hydrogen,
[0616] Me, i Pr, t Bu, CN, CF3,
[0617] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0618] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0619] Me, i Pr, tCarbazolyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0620] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0621] and N(Ph)2.
[0622] In a further embodiment of the present invention, the organic molecule comprises or is composed of the structure of the formula Iaa, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0623] hydrogen,
[0624] Me,
[0625] i Pr,
[0626] t Bu,
[0627] CN,
[0628] CF3,
[0629] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0630] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0631] Me, i Pr, t Pyrimidinyl optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph, and
[0632] Me, i Pr, tTriazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph.
[0633] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iaa, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0634] Hydrogen, Deuterium, OPh, SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0635] C1-C5-alkyl,
[0636] Here, optionally, one or more hydrogen atoms are independently substituted with deuterium (D), CN, CF3, or F;
[0637] C1-C5-alkoxy,
[0638] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0639] C1-C5-thioalkoxy,
[0640] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0641] C2-C5-alkenyl,
[0642] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0643] C2-C5-alkynyl,
[0644] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0645] C6-C 18 -Aril,
[0646] This optionally includes one or more C1-C 5-- Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0647] C3-C 17 -Heteroaryl,
[0648] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0649] N(C6-C 18 -Aril)2,
[0650] N(C3-C 17 -heteroaryl)2; and
[0651] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril).
[0652] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iaa, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0653] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0654] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0655] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Iaa, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0656] Hydrogen, deuterium, i Pr, and
[0657] Ph. optionally substituted with one or more Ph substituents.
[0658] In a specific embodiment, the organic molecule comprises or is composed of the structure of the formula Iaa, where R 2 It is hydrogen in each case.
[0659] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iaa, where R * is selected from a group consisting of doing independently of each other in each case:
[0660] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0661] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0662] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Iaa, where R * is selected from a group consisting of doing independently of each other in each case:
[0663] Hydrogen, deuterium, i Pr, and
[0664] Ph. optionally substituted with one or more Ph substituents.
[0665] In a specific embodiment, the organic molecule comprises or is composed of the structure of the formula Iaa, where R * It is hydrogen in each case.
[0666] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iaa, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0667] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0668] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0669] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Iaa, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0670] Hydrogen, deuterium, i Pr and
[0671] Ph. optionally substituted with one or more Ph substituents.
[0672] In a specific embodiment, the organic molecule comprises or is composed of the structure of the formula Iaa, where R 2 , and R * It is hydrogen in each case.
[0673] In one embodiment, the organic molecule comprises or consists of the structure of the formula Ia-I:
[0674]
[0675] Chemical formula Ia-I
[0676] In one embodiment, the organic molecule comprises or consists of the structure of formula Ia-II:
[0677]
[0678] Chemical formula Ia-II
[0679] In one embodiment, the organic molecule comprises or consists of the structure of the chemical formula Iba:
[0680]
[0681] Chemical formula Iba
[0682] Here, R Yis a single bond binding site that connects the first chemical moiety to the second chemical moiety of chemical formula IIb.
[0683] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R * is selected from a group consisting of doing independently of each other in each case:
[0684] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0685] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0686] In one embodiment of the present invention, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0687] hydrogen,
[0688] Me, i Pr, t Bu, CN, CF3,
[0689] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0690] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0691] Me, i Pr, t Carbazolyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0692] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0693] and N(Ph)2.
[0694] In a further embodiment of the present invention, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0695] hydrogen,
[0696] Me,
[0697] i Pr,
[0698] t Bu,
[0699] CN,
[0700] CF3,
[0701] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0702] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0703] Me, i Pr, t Pyrimidinyl optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph, and
[0704] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph.
[0705] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0706] Hydrogen, Deuterium, OPh, SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0707] C1-C5-alkyl,
[0708] Here, optionally, one or more hydrogen atoms are independently substituted with deuterium (D), CN, CF3, or F;
[0709] C1-C5-alkoxy,
[0710] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0711] C1-C5-thioalkoxy,
[0712] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0713] C2-C5-alkenyl,
[0714] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0715] C2-C5-alkynyl,
[0716] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0717] C6-C 18 -Aril,
[0718] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0719] C3-C 17 -Heteroaryl,
[0720] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0721] N(C6-C 18 -Aril)2,
[0722] N(C3-C 17 -heteroaryl)2; and
[0723] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril).
[0724] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0725] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0726] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0727] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0728] Hydrogen, deuterium, i Pr, and
[0729] Ph. optionally substituted with one or more Ph substituents.
[0730] In a specific embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 It is hydrogen in each case.
[0731] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R * is selected from a group consisting of doing independently of each other in each case:
[0732] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0733] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0734] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R * is selected from a group consisting of doing independently of each other in each case:
[0735] Hydrogen, deuterium, i Pr, and
[0736] Ph. optionally substituted with one or more Ph substituents.
[0737] In a specific embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R * It is hydrogen in each case.
[0738] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0739] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0740] Me, i Pr, tPh. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0741] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0742] Hydrogen, deuterium, i Pr and
[0743] Ph. optionally substituted with one or more Ph substituents.
[0744] In a specific embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 , and R * It is hydrogen in each case.
[0745] In one embodiment, the organic molecule comprises or consists of the structure of formula Ia-III:
[0746]
[0747] Chemical formula Ia-III
[0748] In one embodiment, the organic molecule comprises or consists of the structure of formulas Ia-IV:
[0749]
[0750] Chemical formula Ia-IV
[0751] In one embodiment, the organic molecule comprises or consists of the structure of the chemical formula Iba:
[0752]
[0753] Chemical formula Iba,
[0754] Here, R Z is a single bond binding site that connects the first chemical moiety to the second chemical moiety of chemical formula IIa.
[0755] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R * is selected from a group consisting of doing independently of each other in each case:
[0756] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0757] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0758] In one embodiment of the present invention, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 is selected from a group consisting of those who do it independently:
[0759] hydrogen,
[0760] Me, i Pr, t Bu, CN, CF3,
[0761] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0762] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0763] Me, i Pr, t Carbazolyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0764] Me, i Pr, tTriazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0765] and N(Ph)2.
[0766] In a further embodiment of the present invention, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 is selected from a group consisting of those who do it independently:
[0767] hydrogen,
[0768] Me,
[0769] i Pr,
[0770] t Bu,
[0771] CN,
[0772] CF3,
[0773] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0774] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0775] Me, i Pr, t Pyrimidinyl optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph, and
[0776] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph.
[0777] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0778] Hydrogen, Deuterium, OPh, SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0779] C1-C5-alkyl,
[0780] Here, optionally, one or more hydrogen atoms are independently substituted with deuterium (D), CN, CF3, or F;
[0781] C1-C5-alkoxy,
[0782] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0783] C1-C5-thioalkoxy,
[0784] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0785] C2-C5-alkenyl,
[0786] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0787] C2-C5-alkynyl,
[0788] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0789] C6-C 18 -Aril,
[0790] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0791] C3-C 17 -Heteroaryl,
[0792] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0793] N(C6-C 18 -Aril)2,
[0794] N(C3-C 17 -heteroaryl)2; and
[0795] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril).
[0796] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0797] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0798] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0799] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0800] Hydrogen, deuterium, i Pr, and
[0801] Ph. optionally substituted with one or more Ph substituents.
[0802] In a specific embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 It is hydrogen in each case.
[0803] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R * is selected from a group consisting of doing independently of each other in each case:
[0804] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0805] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0806] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R * is selected from a group consisting of doing independently of each other in each case:
[0807] Hydrogen, deuterium, i Pr, and
[0808] Ph. optionally substituted with one or more Ph substituents.
[0809] In a specific embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R * It is hydrogen in each case.
[0810] In one embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0811] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0812] Me, i Pr, tPh. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0813] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0814] Hydrogen, deuterium, i Pr and
[0815] Ph. optionally substituted with one or more Ph substituents.
[0816] In a specific embodiment, the organic molecule comprises or is composed of the structure of the formula Iba, where R 2 , and R * It is hydrogen in each case.
[0817] In one embodiment, the organic molecule comprises or consists of the structure of the formula Ib-I:
[0818]
[0819] Chemical formula Ib-I
[0820] In one embodiment, the organic molecule comprises or consists of the structure of the formula Ib-II:
[0821]
[0822] Chemical formula Ib-II
[0823] In one embodiment, the organic molecule comprises or consists of the structure of the chemical formula Ibb:
[0824]
[0825] Chemical formula Ibb,
[0826] Here, R Y is a single bond binding site that connects the first chemical moiety to the second chemical moiety of chemical formula IIb.
[0827] In one embodiment, the organic molecule comprises or is composed of the structure of the chemical formula Ibb, where R * is selected from a group consisting of doing independently of each other in each case:
[0828] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0829] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0830] In one embodiment of the present invention, the organic molecule comprises or is composed of the structure of the formula Ibb, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0831] hydrogen,
[0832] Me, i Pr, t Bu, CN, CF3,
[0833] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0834] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0835] Me, i Pr, t Carbazolyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0836] Me, i Pr, tTriazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0837] and N(Ph)2.
[0838] In a further embodiment of the present invention, the organic molecule comprises or is composed of the structure of the formula Ibb, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0839] hydrogen,
[0840] Me,
[0841] i Pr,
[0842] t Bu,
[0843] CN,
[0844] CF3,
[0845] Me, i Pr, t Ph optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph,
[0846] Me, i Pr, t Pyridinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph,
[0847] Me, i Pr, t Pyrimidinyl optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph, and
[0848] Me, i Pr, t Triazinyl selectively substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph.
[0849] In one embodiment, the organic molecule comprises or is composed of the structure of the chemical formula Ibb, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0850] Hydrogen, Deuterium, OPh, SPh, CF3, CN, F, Si(C1-C5-alkyl)3, Si(Ph)3,
[0851] C1-C5-alkyl,
[0852] Here, optionally, one or more hydrogen atoms are independently substituted with deuterium (D), CN, CF3, or F;
[0853] C1-C5-alkoxy,
[0854] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0855] C1-C5-thioalkoxy,
[0856] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0857] C2-C5-alkenyl,
[0858] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0859] C2-C5-alkynyl,
[0860] Here, optionally, one or more hydrogen atoms are substituted independently with deuterium, CN, CF3, or F;
[0861] C6-C 18 -Aril,
[0862] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0863] C3-C 17 -Heteroaryl,
[0864] This optionally includes one or more C1-C 5- - Substituted with an alkyl substituent, Ph, CN, CF3, or F;
[0865] N(C6-C 18 -Aril)2,
[0866] N(C3-C 17 -heteroaryl)2; and
[0867] N(C3-C 17 -heteroaryl)(C6-C 18 -Aril).
[0868] In one embodiment, the organic molecule comprises or is composed of the structure of the chemical formula Ibb, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0869] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0870] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0871] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Ibb, where R 2 is selected from a group consisting of doing independently of each other in each case:
[0872] Hydrogen, deuterium, i Pr, and
[0873] Ph. optionally substituted with one or more Ph substituents.
[0874] In a specific embodiment, the organic molecule comprises or is composed of the structure of the chemical formula Ibb, where R 2 It is hydrogen in each case.
[0875] In one embodiment, the organic molecule comprises or is composed of the structure of the chemical formula Ibb, where R * is selected from a group consisting of doing independently of each other in each case:
[0876] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0877] Me, i Pr, t Ph. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0878] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Ibb, where R * is selected from a group consisting of doing independently of each other in each case:
[0879] Hydrogen, deuterium, i Pr, and
[0880] Ph. optionally substituted with one or more Ph substituents.
[0881] In a specific embodiment, the organic molecule comprises or is composed of the structure of the chemical formula Ibb, where R * It is hydrogen in each case.
[0882] In one embodiment, the organic molecule comprises or is composed of the structure of the chemical formula Ibb, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0883] Hydrogen, Deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and
[0884] Me, i Pr, tPh. optionally substituted with one or more substituents independently selected from the group consisting of Bu and Ph.
[0885] In a preferred embodiment, the organic molecule comprises or is composed of the structure of the formula Ibb, where R 2 , and R * is selected from a group consisting of doing independently of each other in each case:
[0886] Hydrogen, deuterium, i Pr and
[0887] Ph. optionally substituted with one or more Ph substituents.
[0888] In a specific embodiment, the organic molecule comprises or is composed of the structure of the chemical formula Ibb, where R 2 , and R * It is hydrogen in each case.
[0889] In one embodiment, the organic molecule comprises or consists of the structure of the formula Ib-III:
[0890]
[0891] Chemical formula Ib-III
[0892] In one embodiment, the organic molecule comprises or consists of the structure of formula Ib-IV:
[0893]
[0894] Chemical formula Ib-IV.
[0895] As used throughout this specification, the terms “aryl” and “aromatic” may be understood in the broadest sense as any monocyclic, bicyclic, or polycyclic aromatic moiety. Thus, an aryl group comprises 6 to 60 aromatic ring atoms. A heteroaryl group comprises 5 to 60 aromatic ring atoms, at least one of which is a heteroatom. Nevertheless, throughout this specification, the number of aromatic ring atoms may be given by the subscript number in the definition of a specific substituent. In particular, a heteroaromatic ring comprises 1 to 3 heteroatoms. Additionally, the terms “heteroaryl” and “heteroaromatic” may be understood in the broadest sense as any monocyclic, bicyclic, or polycyclic heteroaromatic moiety comprising at least one heteroatom. The heteroatom may be the same or different in each case and may be individually selected from the group consisting of N, O, and S. Accordingly, the term “arylene” refers to a divalent substituent that possesses two bonding sites for other molecular structures and acts as a linker structure. In exemplary embodiments, where a group is defined differently from the definition given herein, for example, where the number of aromatic ring atoms or heteroatoms is different from the given definition, the definition in the exemplary embodiments applies. According to the present invention, a condensed (ringed) aromatic or heteroaromatic polycyclic ring is composed of two or more single aromatic or heteroaromatic rings that form a polycyclic ring through a condensation reaction.
[0896] In particular, as used throughout this specification, the term “aryl group heteroaryl group” refers to benzene, naphthalene, anthracene, phenanthrene, pyrene, dihydropyrene, chrysene, perylene, fluoranthene, benzanthracene, benzphenanthrene, tetracene, pentacene, benzpyrene, furan, benzofuran, isobenzofuran, dibenzofuran, thiophene, benzothiophene, isobenzothiophene, dibenzothiophene; Pyrrole, Indole, Isoindole, Carbazole, Pyridine, Quinoline, Isoquinoline, Acridine, Fenantridine, Benzo-5,6-quinoline, Benzo-6,7-quinoline, Benzo-7,8-quinoline, Phenothiazine, Fenoxazine, Pyrazol, Indazole, Imidazole, Benzimidazole, Naphthoimidazole, Fenantroimidazole, Pyridoidazole, Pyrazinoimidazole, Quinoxalinoimidazole, Oxazole, Benzooxazole, Naphthoxazole, Anthroxazole, Fenantroxazole, Isooxazole, 1,2-Thiaazole, 1,3-Thiaazole, Benzothiazole, Pyridazine, Benzopyridazine, Pyrimidine, Benzopyrimidine, 1,3,5-Triazine, Quinoxaline, Pyrazine, It includes a group that can be bonded through any position of an aromatic or heteroaromatic group derived from phenazine, naftiridine, carbolin, benzocarbolin, phenanthroline, 1,2,3-triazole, 1,2,4-triazole, benzotriazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,2,3,4-tetrazine, purine, pteridine, indolizine and benzothiadiazole or a combination of the groups mentioned above.
[0897] As used throughout this specification, the term “annular group” may be understood in its broadest sense as any single, double, or polycyclic moiety.
[0898] As used throughout this specification, the term “biphenyl” may be understood in the broadest sense as ortho-biphenyl, meta-biphenyl, or para-biphenyl as a substituent, where ortho, meta, and para are defined in relation to the binding position to different chemical moiety.
[0899] As used throughout this specification, the term “terphenyl” may be understood in the broadest sense as a substituent as 3-ortho-terphenyl, 4-ortho-terphenyl, 4-meta-terphenyl, 5-meta-terphenyl, 2-para-terphenyl, or 3-para-terphenyl, where ortho, meta, and para are defined in relation to their positions relative to the pH moiety, and “2-,” “3-,” “4-,” and “5-” are defined in relation to their binding positions relative to other chemical moiety, i.e.:
[0900]
[0901] 3-Ortho-terphenyl 4-Ortho-terphenyl
[0902]
[0903] 4-meta-terphenyl 5-meta-terphenyl 2-meta-terphenyl
[0904]
[0905] 2-paraterphenyl
[0906] Here, # indicates the binding site for a different chemical moiety.
[0907] As used throughout this specification, the term “naphthyl” may be understood in its broadest sense as 1-naphthyl and 2-naphthyl as naphthalene substituents, where “1-” and “2-” are defined in relation to their binding positions to different chemical moiety, i.e.:
[0908]
[0909] 1-Naphthyl 2-Naphthyl
[0910] Here, # indicates the binding site for a different chemical moiety.
[0911] As used throughout this specification, the term “anthracene” may be understood in its broadest sense as 1-anthracenyl, 2-anthracenyl, and 9-anthracenyl as substituents, where “1-,” “2-,” and “9-” are defined in relation to their binding positions to different chemical moiety, i.e.:
[0912]
[0913] 1-Anthracenyl 2-Anthracenyl 9-Anthracenyl
[0914] Here, # indicates the binding site for a different chemical moiety.
[0915] As used throughout this specification, the term “alkyl group” may be understood in the broadest sense as any linear, branched, or cyclic alkyl substituent. In particular, the term “alkyl” refers to the substituents methyl (Me), ethyl (Et), and n-propyl ( n Pr), i-profile( i Pr), cyclopropyl, n-butyl ( n Bu), i-butyl ( i Bu), s-butyl( s Bu), t-butyl( tBu), cyclobutyl, 2-methylbutyl, n-pentyl, s-pentyl, t-pentyl, 2-pentyl, neo-pentyl, cyclopentyl, n-hexyl, s-hexyl, t-hexyl, 2-hexyl, 3-hexyl, neo-hexyl, cyclohexyl, 1-methylcyclopentyl, 2-methylpentyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, cycloheptyl, 1-methylcyclohexyl, n-octyl, 2-ethylhexyl, cyclooctyl, 1-bicyclo[2,2,2]octyl, 2-bicyclo[2,2,2]-octyl, 2-(2,6-dimethyl)octyl, 3-(3,7-dimethyl)octyl, adamantyl, 2,2,2-trifluoroethyl, 1,1-dimethyl-n-hex-1-yl, 1,1-dimethyl-n-hept-1-yl, 1,1-dimethyl-n-oct-1-yl, 1,1-dimethyl-n-dec-1-yl, 1,1-dimethyl-n-dodec-1-yl, 1,1-dimethyl-n-tetradec-1-yl, 1,1-dimethyl-n-hexadec-1-yl, 1,1-dimethyl-n-octadec-1-yl, 1,1-diethyl-n-hex-1-yl, 1,1-diethyl-n-hept-1-yl, 1,1-diethyl-n-oct-1-yl, 1,1-diethyl-n-dec-1-yl, 1,1-diethyl-n-dodec-1-yl, 1,1-diethyl-n-tetradec-1-yl, Includes 1,1-diethyl-n-hexadec-1-yl, 1,1-diethyl-n-octadec-1-yl, 1-(n-propyl)-cyclohex-1-yl, 1-(n-butyl)-cyclohex-1-yl, 1-(n-hexyl)-cyclohex-1-yl, 1-(n-octyl)-cyclohex-1-yl, and 1-(n-decyl)-cyclohex-1-yl.
[0916] As used throughout this specification, the term “alkenyl” includes linear, branched, and cyclic alkenyl substituents. The term “alkenyl group” includes, for example, substituents such as ethenyl, propenyl, butenyl, pentenyl, cyclopentenyl, hexenyl, cyclohexenyl, heptenyl, cycloheptenyl, octenyl, cyclooctenyl, or cyclooctadienyl.
[0917] As used throughout this specification, the term “alkynyl” includes linear, branched, and cyclic alkynyl substituents. The term “alkynyl group” includes, for example, ethinyl, propynyl, butynyl, fentinyl, hexinyl, heptynyl, or octinyl.
[0918] As used throughout this specification, the term “alkoxy” includes linear, branched, and cyclic alkoxy substituents. The term “alkoxy group” includes, for example, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy, and 2-methylbutoxy.
[0919] As used throughout this specification, the term “thioalkoxy” comprises linear, branched, and cyclic thioalkoxy substituents, wherein the O of the exemplary alkoxy group is substituted with S.
[0920] The terms “halogen” and “halo” as used throughout this specification may be understood in the broadest sense as preferably fluorine, chlorine, bromine, or iodine.
[0921] Hydrogen (H) may also be substituted with deuterium in each case whenever mentioned in this specification.
[0922] When a molecular fragment is described as a substituent or attached to another moiety, the designation may be described as if it were a fragment (e.g., naphthyl, dibenzofuryl) or as if it were the whole molecule (e.g., naphthalene, dibenzofuran). As used herein, these different ways of referring to a substituent or an attached fragment are considered equivalent.
[0923] In one embodiment of the present invention, in a DCM containing 0.001 mg / mL of organic molecules at room temperature, said organic molecules according to the present invention have an emission peak in the visible light or nearest ultraviolet (UV) range, i.e., a wavelength range of 380 nm to 800 nm, and have a full width at half maximum value of less than 0.35 eV, preferably less than 0.30 eV, more preferably less than 0.26 eV, even more preferably less than 0.22 eV, or even less than 0.18 eV.
[0924] The energy of the first excited triplet state T1 is determined from the onset of the emission spectrum at a low temperature, typically 77 K. Phosphorescence is generally observed in the steady-state spectrum of a film of 2% emitter and 98% poly(methyl methacrylate) (PMMA). Therefore, the triplet energy can be determined as the onset of the phosphorescence spectrum. For fluorescent emitter molecules, the energy of the first excited triplet state T1 is determined from the onset of the delayed emission spectrum at 77 K.
[0925] The start of the emission spectrum is determined by calculating the intersection point of the tangent to the emission spectrum and the x-axis. The tangent to the emission spectrum is set on the high-energy side of the emission band and at the point of maximum half the maximum intensity of the emission spectrum.
[0926] In one embodiment, the organic molecule according to the present invention has an onset of an emission spectrum that is energetically close to maximum emission in a DCM containing 0.001 mg / mL of the organic molecule at room temperature, i.e., the energy difference between the onset of the emission spectrum and the energy of maximum emission is less than 0.14 eV, preferably less than 0.13 eV, or even less than 0.12 eV, and the full width at half maximum (FWHM) of the organic molecule is less than 0.35 eV, preferably less than 0.30 eV, more preferably less than 0.26 eV, even more preferably less than 0.22 eV, or even less than 0.18 eV, so that consequently the CIEy coordinate is less than 0.20, preferably less than 0.18, more preferably less than 0.16, or even less than 0.14.
[0927] A further aspect of the present invention relates to the use of the organic molecules of the present invention as an electroluminescent emitter or absorber, and / or a host material and / or an electron transport material, and / or a hole injection material, and / or a hole blocking material in a photoelectronic device.
[0928] A preferred embodiment relates to the use of an organic molecule according to the present invention as a light-emitting emitter in a photoelectronic device.
[0929] An optoelectronic device can be understood in the broadest sense as any device based on an organic material suitable for emitting light in the visible light or near-ultraviolet range, that is, in the wavelength range of 380 to 800 nm. More preferably, the optoelectronic device can emit light in the visible light range, that is, in the wavelength range of 400 nm to 800 nm.
[0930] In relation to these applications, optoelectronic devices are selected more specifically from the group consisting of the following:
[0931] · Organic Light Emitting Diode (OLED),
[0932] · Luminescent electrochemical cell,
[0933] · OLED sensors, especially gas and vapor sensors that are not completely isolated from the outside,
[0934] · Organic diode,
[0935] · Organic solar cells,
[0936] · Organic transistor,
[0937] · Organic field-effect transistor,
[0938] · Organic lasers, and
[0939] · Down-conversion element.
[0940] In a preferred embodiment related to such applications, the optoelectronic device is a device selected from the group consisting of organic light-emitting diodes (OLEDs), light-emitting electrochemical cells (LECs), and light-emitting transistors.
[0941] For the above application, the fraction of the organic molecule according to the present invention in the light-emitting layer of the optoelectronic device, more specifically in the OLED, is 0.1 wt% to 99 wt%, more specifically 1 wt% to 80 wt%. In an alternative embodiment, the proportion of the organic molecule in the light-emitting layer is 100 wt%.
[0942] In one embodiment, the light-emitting layer further comprises an organic molecule according to the present invention as well as a host material having triplet (T1) and singlet (S1) energy levels higher than the triplet (T1) and singlet (S1) energy levels of the organic molecule.
[0943] A further aspect of the present invention relates to a composition comprising or made thereof of the following:
[0944] (a) at least one organic molecule according to the present invention in the form of an emitter, and
[0945] (b) one or more triplet-triplet annihilation (TTA) host materials different from the organic molecule according to the present invention, and
[0946] (c) Optionally, one or more TADF materials,
[0947] (d) Optionally, one or more dyes and / or one or more solvents.
[0948] A further aspect of the present invention relates to a composition comprising or made thereof of the following:
[0949] (a) at least one organic molecule according to the present invention in the form of an emitter, and
[0950] (b) one or more host materials different from the organic molecule according to the present invention, and
[0951] (c) One or more TADF substances.
[0952] A further aspect of the present invention relates to a composition comprising or made thereof of the following:
[0953] (a) at least one organic molecule according to the present invention in the form of an emitter, and
[0954] (b) one or more host materials different from the organic molecule according to the present invention, and
[0955] (c) One or more phosphorescent materials.
[0956] In a specific embodiment, the light-emitting layer EML comprises (or essentially comprises) a composition including or consisting of the following:
[0957] (i) 0.1-10 wt%, preferably 0.5-5 wt%, particularly 1-3 wt% of one or more organic molecules according to the present invention;
[0958] (ii) 5-99 wt%, preferably 15-85 wt%, particularly 20-75 wt% of one or more host compounds H; and
[0959] (iii) 0.9-94.9 wt%, preferably 14.5-80 wt%, particularly 24-77 wt%, of one or more additional host compounds D having a structure different from the structure of the molecule according to the present invention; and
[0960] (iv) optionally, 0-94 wt%, preferably 0-65 wt%, particularly 0-50 wt% of solvent; and
[0961] (v) Optionally, 0 to 30 weight%, particularly 0 to 20 weight%, preferably 0 to 5 weight% of one or more additional emitter molecules F having a structure different from the structure of the molecule of the present invention.
[0962] Composition having one or more TTA host materials
[0963] In a preferred embodiment, in the optoelectronic device of the present invention, the light-emitting layer B comprises (or consists of):
[0964] (i) 10-84 wt% of TTA material H N ;
[0965] (ii) 0-30 wt% of TADF material E B ; and
[0966] (iii) 0.1-10 wt% of the emitter according to the present invention; and optionally,
[0967] (iv) 0-74 wt% of one or more solvents.
[0968] In a preferred embodiment, the percentage numbers of (i) to (v) are added together to 100 weight%.
[0969] In another preferred embodiment, in the optoelectronic device of the present invention, the light-emitting layer B comprises (or consists of):
[0970] (i) 56-90 wt% of TTA material H N ;
[0971] (ii) 0-5 wt% of TADF material E B ; and
[0972] (iii) 0.5-5 wt% of the emitter according to the present invention; and optionally,
[0973] (iv) 0-34 wt% of one or more solvents.
[0974] In a preferred embodiment, the percentage numbers of (i) to (v) are added together to 100 weight%.
[0975] Composition having one or more TADF materials
[0976] In one embodiment, the light-emitting layer B comprises the following:
[0977] (i) 10–89.9 wt% of one or more p-host compounds H P ;
[0978] (ii) 0-79.9 wt% of one or more n-host compounds H N ;
[0979] (iii) 10-50 wt% of one or more TADF materials E B ; and
[0980] (iv) 0.1-10 wt% of one or more emitters according to the present invention; and
[0981] (v) 0-79.9 wt% of one or more solvents.
[0982] In one embodiment, the light-emitting layer B comprises the following:
[0983] (i) 22-87.5 wt% of one or more p-host compounds H P ;
[0984] (ii) 0-65.5 wt% of one or more n-host compounds H N ;
[0985] (iii) 12-40 wt% of one or more TADF materials E B ; and
[0986] (iv) 0.5-5 wt% of one or more emitters according to the present invention; and
[0987] (v) 0-65.5 wt% of one or more solvents.
[0988] A composition having one or more phosphorescent materials
[0989] H N In this optional preferred embodiment, in the optoelectronic device of the present invention, the light-emitting layer B comprises (or consists of):
[0990] (i) 10-84.9 wt% of host compound H P ;
[0991] (ii) 0-84.9 wt% of host compound H N ;
[0992] (iii) 5-15 wt% of phosphorescent material E B ; and
[0993] (iv) 0.1-10 wt% of the emitter according to the present invention; and optionally,
[0994] (v) 0-84.9 wt% of one or more solvents.
[0995] H N In this optional preferred embodiment, in the optoelectronic device of the present invention, the light-emitting layer B comprises (or consists of):
[0996] (i) 22-70.5 wt% of host compound H P ;
[0997] (ii) 0-72.5 wt% of host compound H N ;
[0998] (iii) 5-10 wt% of phosphorescent material E B ; and
[0999] (iv) 0.5-5 wt% of the emitter according to the present invention; and optionally,
[1000] (v) 0-72.5 wt% of one or more solvents.
[1001] Preferably, energy can be transferred from a host compound H to one or more organic molecules according to the present invention, in particular from the first excited triplet state T1(H) of the host compound H to the first excited triplet state T1(E) of one or more organic molecules E according to the present invention, or from the first excited singlet state S1(H) of the host compound H to the first excited singlet state S1(E) of one or more organic molecules E according to the present invention.
[1002] In one embodiment, the host compound H has an energy E in the range of -5 to -6.5 eV. HOMO Having a highest-level occupied molecular orbital HOMO (H) having (H), and at least one additional host compound D has energy E HOMO It has a highest-level occupied molecular orbital HOMO(D) having (D), where E HOMO (H) > E HOMO (D) is.
[1003] In an additional embodiment, the host compound H has energy E LUMO Having a lowest-level unoccupied molecular orbital LUMO(H) having (H), and at least one additional host compound D has energy E LUMO (D) having a lowest level unoccupied molecular orbital LUMO(D), where E LUMO (H) > E LUMO (D) is.
[1004] In one embodiment, the host compound H has energy E HOMO Highest level occupied molecular orbital HOMO(H) with (H) and energy E LUMO Having a lowest-level unoccupied molecular orbital LUMO(H) with (H),
[1005] At least one additional host compound D has energy E HOMO Highest level occupied molecular orbital HOMO(D) with (D) and energy E LUMOIt has a lowest level unoccupied molecular orbital LUMO(D) having (D), and
[1006] The organic molecule E according to the present invention is energy E HOMO Highest level occupied molecular orbital HOMO(E) with (E) and energy E LUMO It has a lowest-level unoccupied molecular orbital LUMO(E) having (E), and
[1007] Here
[1008] E HOMO (H) > E HOMO (D) and the energy level (E) of the highest level occupied molecular orbital HOMO(E) of the organic molecule E according to the present invention HOMO (E)) and the highest level occupied molecular orbital HOMO(H) energy level of host compound H (E HOMO The difference between (H)) is between -0.5 eV and 0.5 eV, more preferably between -0.3 eV and 0.3 eV, even more preferably between -0.2 eV and 0.2 eV or even between -0.1 eV and 0.1 eV;
[1009] E LUMO (H) > E LUMO (D) and the energy level (E) of the lowest level unoccupied molecular orbital LUMO(E) of the organic molecule E according to the present invention LUMO The energy level difference (E) between (E)) and the lowest level unoccupied molecular orbital LUMO (D) of at least one additional host compound D LUMO (D)) is between -0.5 eV and 0.5 eV, more preferably between -0.3 eV and 0.3 eV, even more preferably between -0.2 eV and 0.2 eV or even between -0.1 eV and 0.1 eV.
[1010] In one embodiment of the present invention, host compound D and / or host compound H are thermally activated delayed fluorescence (TADF) materials. The TADF material is 2500 cm⁻¹ -1ΔE, which corresponds to the energy difference between the first excited singlet state (S1) and the first excited triplet state (T1), less than ST Indicates a value. Preferably, the TADF material is 3000 cm⁻¹ -1 Less than, more preferably 1500 cm -1 Less than, even more preferably 1000 cm -1 Less than or even 500 cm -1 ΔE less than ST Represents the value.
[1011] In one embodiment, host compound D is a TADF material, and host compound H is 2500 cm -1 ΔE greater than ST Indicates a value. In a specific embodiment, host compound D is a TADF material, and host compound H is selected from the group consisting of CBP, mCP, mCBP, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzothiophen-2-yl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzofuranyl)phenyl]-9H-carbazole and 9-[3,5-bis(2-dibenzothiophenyl)phenyl]-9H-carbazole.
[1012] In one embodiment, host compound H is a TADF material and host compound D is 2500 cm -1 ΔE greater than ST Indicates a value. In a specific embodiment, host compound H is a TADF material, and host compound D is selected from the group consisting of T2T (2,4,6-tris(biphenyl-3-yl)-1,3,5-triazine), T3T (2,4,6-tris(triphenyl-3-yl)-1,3,5-triazine) and / or TST (2,4,6-tris(9,9'-spirobifluoren-2-yl)-1,3,5-triazine).
[1013] In a further aspect, the present invention relates to an optoelectronic device comprising an organic molecule or composition of the type described herein, more specifically, to a device selected from the group consisting of an organic light-emitting diode (OLED), a light-emitting electrochemical cell, an OLED sensor (in particular, a gas and vapor sensor that is not completely isolated from the outside), an organic diode, an organic solar cell, an organic transistor, an organic field-effect transistor, an organic laser, and a down-conversion device.
[1014] In a preferred embodiment, the optoelectronic device is a device selected from the group consisting of an organic light-emitting diode (OLED), a light-emitting electrochemical cell (LEC), and a light-emitting transistor.
[1015] In one embodiment of the optoelectronic device of the present invention, the organic molecule E according to the present invention is used as a light-emitting material in the light-emitting layer EML.
[1016] In one embodiment of the optoelectronic device of the present invention, the light-emitting layer EML is composed of the composition according to the present invention as described herein.
[1017] If the optoelectronic device is an OLED, it may have a layer structure such as the following, for example.
[1018] 1. Substrate
[1019] 2. Anode Layer A
[1020] 3. Hole injection layer, HIL
[1021] 4. Hole Transport Layer, HTL
[1022] 5. Electron Blocking Layer, EBL
[1023] 6. Emitting layer, EML
[1024] 7. Hole Blocking Layer, HBL
[1025] 8. Electron Transport Layer, ETL
[1026] 9. Electron injection layer, EIL
[1027] 10. Cathode layer,
[1028] Here, the OLED may selectively include each layer selected from the group of HIL, HTL, EBL, HBL, ETL, and EIL, different layers may be merged, and the OLED may include one or more layers of each layer type defined above.
[1029] Furthermore, in one embodiment, the optoelectronic device may include one or more protective layers that protect the device from damage caused by exposure to harmful types of environments, for example, including moisture, vapor, and / or gas.
[1030] In one embodiment of the present invention, the optoelectronic device is an OLED having the following inverted layer structure:
[1031] 1. Substrate
[1032] 2. Cathode layer
[1033] 3. Electron injection layer, EIL
[1034] 4. Electron Transport Layer, ETL
[1035] 5. Hole Blocking Layer, HBL
[1036] 6. Emitting layer, B
[1037] 7. Electron Blocking Layer, EBL
[1038] 8. Hole Transport Layer, HTL
[1039] 9. Hole injection layer, HIL
[1040] 10. Anode Layer A
[1041] Here, the OLED may selectively include each layer selected from the group of HIL, HTL, EBL, HBL, ETL, and EIL, and different layers may be merged, and the OLED may include one or more layers of each layer type defined above.
[1042] In one embodiment of the present invention, the optoelectronic device is an OLED that may have a stacked structure. In this structure, unlike a typical arrangement where OLEDs are placed side by side, individual units are stacked on top of each other. Mixed light may be generated by the OLED having the stacked structure, and in particular, white light may be generated by stacking blue, green, and red OLEDs. Additionally, the OLED having the stacked structure may include a charge generation layer (CGL), which is generally located between two OLED subunits and is generally composed of an n-doped layer and a p-doped layer, and generally the n-doped layer of one CGL is located closer to the anode layer.
[1043] In one embodiment of the present invention, the optoelectronic device is an OLED comprising two or more light-emitting layers between an anode and a cathode. In particular, such a so-called tandem OLED comprises three light-emitting layers, wherein one light-emitting layer emits red light, one light-emitting layer emits green light, and one light-emitting layer emits blue light, and optionally may include additional layers such as a charge generation layer, a charge blocking layer, or a charge transport layer between the individual light-emitting layers. In a further embodiment, the light-emitting layers are stacked adjacently. In a further embodiment, the tandem OLED comprises a charge generation layer between each of the two light-emitting layers. Additionally, adjacent light-emitting layers or light-emitting layers separated by a charge generation layer may be combined.
[1044] The substrate may be formed from any material or a composition of materials. Most frequently, a glass slide is used as the substrate. Alternatively, a thin metal layer (e.g., copper, gold, silver, or aluminum film) or a plastic film or slide may be used. This may allow for a higher level of flexibility. The anode layer A is composed of a material that allows for obtaining a mostly (essentially) transparent film. Since at least one of the two electrodes must be (essentially) transparent to allow light emission from the OLED, either the anode layer A or the cathode layer C is transparent. Preferably, the anode layer A contains a large amount of transparent conductive oxides (TCOs) or is even composed of them. This anode layer A may include, for example, indium tin oxide, aluminum zinc oxide, fluorine-doped tin oxide, indium zinc oxide, PbO, SnO, zirconium oxide, molybdenum oxide, vanadium oxide, tungsten oxide, graphite, doped Si, doped Ge, doped GaAs, doped polyaniline, doped polypyrrole and / or doped polythiophene.
[1045] Anode layer A is (essentially) indium tin oxide (ITO) (e.g., (InO3) 0.9 (SnO2) 0.1It can be composed of ). The roughness of the anode layer (A) caused by the transparent conductive oxide (TCO) can be offset by using a hole injection layer (HIL). Additionally, the HIL can facilitate the injection of quasi-charge carriers (i.e., holes) in that it facilitates the transport of quasi-charge carriers from the TCO to the hole transport layer (HTL). The hole injection layer (HIL) may comprise poly-3,4-ethylenedioxythiophene (PEDOT), polystyrene sulfonate (PSS), MoO2, V2O5, CuPC, or CuI, particularly a mixture of PEDOT and PSS. The hole injection layer (HIL) can also prevent the diffusion of metal from the anode layer (A) to the hole transport layer (HTL). For example, HIL is PEDOT:PSS (poly-3,4-ethylenedioxythiophene:polystyrene sulfonate), PEDOT (poly-3,4-ethylenedioxythiophene), mMTDATA (4,4',4''-tris[phenyl(m-tolyl)amino]triphenylamine), Spiro-TAD (2,2',7,7'-tetrakis(n,n-diphenylamino)-9,9'-spirobifluorene), DNTPD (N1,N1'-(phenyl-4,4'-diyl)bis(N1-phenyl-N4,N4-di-m-tolylbenzene-1,4-diamine), NPB (N,N'-nis-(1-naphthalenyl)-N,N'-bis-phenyl-(1,1'-biphenyl)-4,4'-diamine), It may include NPNPB (N,N'-diphenyl-N,N'-di-[4-(N,N-diphenyl-amino)phenyl]benzidine), MeO-TPD (N,N,N',N'-tetrakis(4-methoxyphenyl)benzidine), HAT-CN (1,4,5,8,9,11-hexaazatriphenylene-hexacarbonitrile) and / or spiro-NPD (N,N'-diphenyl-N,N'-bis-(1-naphthyl)-9,9'-spirobifluorene-2,7-diamine).
[1046] A hole transport layer (HTL) is typically located adjacent to the anode layer A or the hole injection layer (HIL). Any hole transport compound may be used here. For example, electron-rich heteroaromatic compounds such as triarylamines and / or carbazoles may be used as hole transport compounds. The HTL can reduce the energy barrier between the anode layer (A) and the emissive layer (EML). The hole transport layer (HTL) may also be an electron blocking layer (EBL). Preferably, the hole transport compound has a triplet state T1 at a relatively high energy level. For example, the hole transport layer (HTL) may comprise a star-shaped heterocyclic ring such as TCTA (tris(4-carbazoyl-9-ylphenyl)amine), poly-TPD (poly(4-butylphenyl-diphenyl-amine)), α-NPD (poly(4-butylphenyl-diphenyl-amine)), TAPC (4,4'-cyclohexylidene-bis[N,N-bis(4-methylphenyl)benzeneamine]), 2-TNATA (4,4',4''-tris[2-naphthyl(phenyl)amino]triphenylamine), Spiro-TAD, DNTPD, NPB, NPNPB, MeO-TPD, HAT-CN and / or TrisPcz (9,9'-diphenyl-6-(9-phenyl-9H-carbazole-3-yl)-9H,9'H-3,3'-bicarbazole). Additionally, the HTL may include a p-doped layer that may consist of an inorganic or organic dopant within an organic hole transport matrix. For example, transition metal oxides such as vanadium oxide, molybdenum oxide, or tungsten oxide may be used as inorganic dopants. For example, tetrafluorotetracyanoquinodimethane (F4-TCNQ), copper-pentafluorobenzoate (Cu(I)pFBz), or transition metal complexes may be used as organic dopants.
[1047] EBL may include, for example, mCP (1,3-bis(carbazole-9-yl)benzene), TCTA, 2-TNATA, mCBP (3,3-di(9H-carbazole-9-yl)biphenyl), tris-Pcz, CzSi (9-(4-tert-butylphenyl)-3,6-bis(triphenylsilyl)-9H-carbazole), and / or DCB (N,N'-dicarbazoleyl-1,4-dimethylbenzene).
[1048] An emitting layer (EML) is generally located adjacent to a hole transport layer (HTL). The emitting layer (EML) comprises at least one emitting molecule. In particular, the EML comprises one or more emitting molecules E according to the present invention. In one embodiment, the emitting layer comprises only organic molecules according to the present invention. Generally, the EML further comprises one or more host materials H. For example, host material H is CBP(4,4'-bis-(N-carbazoleyl)-biphenyl), mCP, mCBP, Sif87(dibenzo[b,d]thiophene-2-yltriphenylsilane), CzSi, Sif88(dibenzo[b,d]thiophene-2-yl)diphenylsilane), DPEPO(bis[2-(diphenylphosphino)phenyl]ether oxide), 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzothiophen-2-yl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzofuranyl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzothiophenyl)phenyl]-9H-carbazole, T2T (2,4,6-tris(biphenyl-3-yl)-1,3,5-triazine), T3T (2,4,6-tris(triphenyl-3-yl)-1,3,5-triazine) and / or TST (2,4,6-tris(9,9'-spirobifluoren-2-yl)-1,3,5-triazine). The host substance H should generally be selected to exhibit first triplet (T1) and first singlet (S1) energy levels that are energetically higher than the first triplet (T1) and first singlet (S1) energy levels of the organic molecule.
[1049] In one embodiment of the present invention, the EML comprises a so-called mixed host system having at least one hole-dominant host and one electron-dominant host. In a specific embodiment, the EML comprises exactly one luminescent organic molecule according to the present invention and T2T as the electron-dominant host, and one selected from CBP, mCP, mCBP, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzothiophen-2-yl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzofuranyl)phenyl]-9H-carbazole and 9-[3,5-bis(2-dibenzothiophenyl)phenyl]-9H-carbazole as the hole-dominant host. In an additional embodiment, the EML comprises 50-80 wt%, preferably 60-75 wt%, of a host selected from CBP, mCP, mCBP, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzothiophen-2-yl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzofuranyl)phenyl]-9H-carbazole and 9-[3,5-bis(2-dibenzothiophenyl)phenyl]-9H-carbazole; 10-45 wt%, preferably 15-30 wt%, of T2T; and 5-40 wt%, preferably 10-30 wt%, of a luminescent molecule according to the present invention.
[1050] An electron transport layer (ETL) may be located adjacent to the emissive layer (EML). Any electron transporter may be used here. For example, electron-deficient compounds such as benzimidazole, pyridine, triazole, oxadiazole (e.g., 1,3,4-oxadiazole), phosphine oxide, and sulfone may be used. The electron transporter may also be a star-shaped heterocyclic ring such as 1,3,5-tri(1-phenyl-1H-benzo[d]imidazole-2-yl)phenyl (TPBi). ETL may include NBphen (2,9-bis(naphthalene-2-yl)-4,7-diphenyl-1,10-phenanthroline), Alq3 (aluminum-tris(8-hydroxyquinoline)), TSPO1 (diphenyl-4-triphenylsilylphenyl-phosphine oxide), BPyTP2 (2,7-di(2,2'-bipyridin-5-yl)triphenyl), Sif87 (dibenzo[b,d]thiophene-2-yltriphenylsilane), Sif88 (dibenzo[b,d]thiophene-2-yl)diphenylsilane), BmPyPhB (1,3-bis[3,5-di(pyridin-3-yl)phenyl]benzene) and / or BTB (4,4'-bis-[2-(4,6-diphenyl-1,3,5-triazinyl)]-1,1'-biphenyl). Optionally, the ETL can be doped with a material such as Liq. The electron transport layer (ETL) can also block holes, or a hole blocking layer (HBL) is introduced.
[1051] HBLs are, for example, BCP(2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline = batocuproin), BAlq(bis(8-hydroxy-2-methylquinoline)-(4-phenylphenoxy)aluminum), NBphen(2,9-bis(naphthalene-2-yl)-4,7-diphenyl-1,10-phenanthroline), Alq3(aluminum-tris(8-hydroxyquinoline)), TSPO1(diphenyl-4-triphenylsilylphenylphosphinoxide), T2T(2,4,6-tris(biphenyl-3-yl)-1,3,5-triazine), T3T(2,4,6-tris(triphenyl-3-yl)-1,3,5-triazine), It may include TST (2,4,6-tris(9,9'-spirobifluoren-2-yl)-1,3,5-triazine) and / or TCB / TCP (1,3,5-tris(N-carbazolyl)benzol / 1,3,5-tris(carbazol)-9-yl)benzene).
[1052] A cathode layer C may be located adjacent to the electron transport layer (ETL). The cathode layer C may comprise, for example, a metal (e.g., Al, Au, Ag, Pt, Cu, Zn, Ni, Fe, Pb, LiF, Ca, Ba, Mg, In, W, or Pd) or a metal alloy, or may be composed of these. For practical reasons, the cathode layer may also be composed of (inherently) opaque metals such as Mg, Ca, or Al. Alternatively, or additionally, the cathode layer C may also comprise graphite and / or carbon nanotubes (CNT). Alternatively, the cathode layer C may also be composed of nanoscale silver wires.
[1053] The OLED may optionally further include a protective layer (which may be referred to as an electron injection layer (EIL)) between the electron transport layer (ETL) and the cathode layer (C). This layer may include lithium fluoride, cesium fluoride, silver, Liq (8-hydroxyquinolinolatolithium), Li2O, BaF2, MgO, and / or NaF.
[1054] Optionally, the electron transport layer (ETL) and / or hole blocking layer (HBL) may also include one or more host compounds H.
[1055] To further adjust the emission spectrum and / or absorption spectrum of the emitting layer (EML), the emitting layer (EML) may further comprise one or more additional emitter molecules (F). Such emitter molecules F may be any emitter molecules known in the art. Preferably, such emitter molecules F are molecules having a structure different from that of molecule E according to the present invention. The emitter molecule F may optionally be a TADF emitter. Alternatively, the emitter molecule F may optionally be a fluorescent and / or phosphorescent emitter molecule capable of shifting the emission spectrum and / or absorption spectrum of the emitting layer EML. Exemplarily, triplet and / or singlet excitons, in the ground state S O Before being relaxed, it is transferred from the organic emitter molecule according to the present invention to the emitter molecule F, which can emit light that is typically red-shifted compared to the light emitted by the organic molecule. Optionally, the emitter molecule F can also induce a two-photon effect (i.e., absorption of two photons of half the energy of the maximum absorption).
[1056] Optionally, the optoelectronic device (e.g., OLED) may be, for example, essentially a white optoelectronic device. For example, such a white optoelectronic device may include at least one (deep) blue emitter molecule and one or more emitter molecules that emit green and / or red light. Then, optionally, there may also be energy transfer between two or more molecules as described above.
[1057] As used herein, unless more specifically defined in a particular paragraph, the color designation of emitted and / or absorbed light is as follows:
[1058] Purple: Wavelength range >380-420 nm;
[1059] Deep blue: wavelength range >420-480 nm;
[1060] Sky blue: wavelength range of >480-500 nm;
[1061] Green: Wavelength range of >500-560 nm;
[1062] Yellow: Wavelength range >560-580 nm;
[1063] Orange: Wavelength range >580-620 nm;
[1064] Red: Wavelength range of >620-800 nm.
[1065] These colors represent maximum luminescence in relation to emitter molecules. Thus, for example, a dark blue emitter has maximum luminescence in the range of >420–480 nm, a sky blue emitter has maximum luminescence in the range of >480–500 nm, a green emitter has maximum luminescence in the range of >500–560 nm, and a red emitter has maximum luminescence in the range of >620–800 nm.
[1066] The green emitter can preferably have a maximum luminescence between 500 and 560 nm, more preferably between 510 and 550 nm, and even more preferably between 520 and 540 nm.
[1067] Further embodiments of the present invention relate to an OLED emitting light having color coordinates CIEx and CIEy close to the color coordinates CIEx (= 0.170) and CIEy (= 0.797) of primary green (CIEx = 0.170 and CIEy = 0.797) as defined in the ITU-R Recommendation BT.2020 (Rec. 2020), which is suitable for use in ultra-high definition (UHD) displays, e.g., UHD-TVs. In this context, the term “close” refers to the range of CIEx and CIEy coordinates provided at the end of this paragraph. In commercial applications, top-emitting (top electrode is transparent) devices are typically used, whereas the test device used throughout the present invention represents a bottom-emitting device (bottom electrode and substrate are transparent). Accordingly, a further aspect of the present invention relates to an OLED that emits light in CIEx color coordinates of 0.06 to 0.34, preferably 0.07 to 0.29, more preferably 0.09 to 0.24, even more preferably 0.12 to 0.22 or even 0.14 to 0.19 and / or 0.14 to 0.19 and / or 0.44 to 0.84, preferably 0.55 to 0.83, more preferably 0.65 to 0.82, even more preferably 0.70 to 0.81 or even 0.75 to 0.8.
[1068] Therefore, an additional aspect of the present invention is 14,500 cd / m 2The invention relates to an OLED that exhibits an external quantum efficiency of more than 10%, more preferably more than 13%, more preferably more than 15%, even more preferably more than 17% or even more than 20%, or exhibits maximum emission at 495 nm to 580 nm, preferably 500 nm to 560 nm, more preferably 510 nm to 550 nm, and much more preferably 515 nm to 540 nm.
[1069] The deep blue emitter may preferably have a maximum emission of less than 480 nm, more preferably less than 470 nm, much more preferably less than 465 nm, or even less than 460 nm. The maximum emission will typically be greater than 420 nm, preferably greater than 430 nm, more preferably greater than 440 nm, or even greater than 450 nm.
[1070] Therefore, an additional aspect of the present invention is 1000 cd / m 2 Exhibiting an external quantum efficiency of greater than 8%, more preferably greater than 10%, more preferably greater than 13%, even more preferably greater than 15% or even greater than 20%, or exhibiting / exhibiting maximum luminescence at 420 nm to 500 nm, preferably 430 nm to 490 nm, more preferably 440 nm to 480 nm, much more preferably 450 nm to 470 nm, or 500 cd / m² 2 The present invention relates to an OLED exhibiting an LT80 value greater than 100h, preferably greater than 200h, more preferably greater than 400h, much more preferably greater than 750h, or even greater than 1000h. Accordingly, a further aspect of the present invention relates to an OLED exhibiting a CIEy color coordinate less than 0.45, preferably less than 0.30, more preferably less than 0.20, or much more preferably less than 0.15, or even less than 0.10.
[1071] Another aspect of the present invention relates to an OLED that emits light from a distinct color point. According to the present invention, the OLED emits light having a narrow emission band (small full width at half maximum (FWHM)). In one aspect, the OLED according to the present invention emits light having a FWHM of the main emission peak of less than 0.30 eV, preferably less than 0.25 eV, more preferably less than 0.20 eV, much more preferably less than 0.19 eV or even less than 0.17 eV.
[1072] Another aspect of the present invention relates to an OLED having CIEx and CIEy color coordinates close to the CIEx (= 0.131) and CIEy (= 0.046) color coordinates of primary blue (CIEx = 0.131 and CIEy = 0.046) as defined in the ITU-R Recommendation BT.2020 (Rec. 2020), and thus suitable for use in ultra-high definition (UHD) displays, e.g., UHD-TVs. Accordingly, a further aspect of the present invention relates to an OLED that emits light in CIEx color coordinates of 0.02 to 0.30, preferably 0.03 to 0.25, more preferably 0.05 to 0.20, even more preferably 0.08 to 0.18 or even 0.10 to 0.15 and / or CIEy color coordinates of 0.00 to 0.45, preferably 0.01 to 0.30, more preferably 0.02 to 0.20, even more preferably 0.03 to 0.15 or even 0.04 to 0.10.
[1073] In a further aspect, the present invention relates to a method for manufacturing a photoelectronic component. In this case, the organic molecule of the present invention is used.
[1074] Optoelectronic devices, particularly OLEDs according to the present invention, can be manufactured by vapor deposition and / or liquid-phase processes of any means. Thus, at least one layer
[1075] - Manufactured through a sublimation process, or
[1076] - Manufactured by an organic vapor deposition process,
[1077] - Manufactured by a carrier gas sublimation process,
[1078] - It can be processed or printed as a solution.
[1079] Methods used to manufacture optoelectronic devices, particularly OLEDs according to the present invention, are known in the art. Different layers are deposited individually and sequentially on a suitable substrate by a subsequent deposition process. The individual layers may be deposited using the same or different deposition methods.
[1080] For example, vapor deposition processes include thermal (co)evaporation, chemical vapor deposition, and physical vapor deposition. For active matrix OLED displays, an AMOLED backplane is used as a substrate. Individual layers can be processed from a solution or dispersion using a suitable solvent. For example, solution deposition processes include spin coating, dip coating, and jet printing. Solution processing can optionally be performed in an inert atmosphere (e.g., a nitrogen atmosphere), and the solvent can be completely or partially removed by means known in the art.
[1081] [Example]
[1082] General synthesis method I
[1083] General synthesis method I provides a method for synthesizing organic molecules according to the present invention, wherein R III = R VIII and; R II , R IV , R VII and R IXis hydrogen, and
[1084] Adjacent substituent R V and R VI , represents a binding site of a single bond connecting a first chemical moiety to a second chemical moiety to form a ring,
[1085] Two adjacent substituents R X and R I ; indicates the bonding site of a single bond connecting a first chemical moiety to another (e.g., second) second chemical moiety to form a ring where X is B, Y is N, and o and p are 0:
[1086]
[1087] I0 (1.00 equivalent) , I0-1 (2.20 equivalents) , Tetrakis(triphenylphosphine)palladium (0) Pd(PPh3)4 (0.04 equivalents; CAS: 14221-01-3), and potassium carbonate (K2CO3; 4.00 equivalents) are stirred overnight at 110 °C in a dioxane:water (4:1 volume ratio) under a nitrogen atmosphere. After cooling to room temperature (RT), the reaction mixture is extracted with DCM and brine, and the phases are separated. The combined organic layers are dried on MgSO4, and then the solvent is removed under reduced pressure. The obtained crude product is purified by recrystallization or column chromatography, and product I1 is obtained as a solid. Corresponding boronic acid may be used instead of the boronic acid ester.
[1088] synthesis AAV2 General procedure for:
[1089]
[1090] I1 (1.00 equivalent) and liquid bromine (4.0 equivalents; CAS 7726-95-6) are stirred overnight at room temperature in dimethylformamide anhydrous (DMF) under a nitrogen atmosphere. The reaction mixture is poured into water. The precipitate is filtered and washed with water and ethanol. The obtained crude product is purified by recrystallization or column chromatography, and the product I2 It is obtained as a solid.
[1091] synthesis AAV3 General procedure for:
[1092]
[1093] Here X H is a halogen selected from the group consisting of Cl, Br, and I. In a specific embodiment, X H is Cl.
[1094] I2 (1.00 equivalents), I2-1 (2.20 equivalents), tris(dibenzylideneacetone)dipalladium Pd2(dba)3 (0.02 equivalents, CAS: 51364-51-3), and sodium tert-butoxide NaO t Bu (4.00 equivalents, CAS: 865-48-5) is stirred in dry toluene under a nitrogen atmosphere. Tri-tert-butyl-phosphine P( t Add Bu)3 (0.08 equivalents, 1 M in toluene, CAS 13716-12-6) and stir the mixture at 80°C until completion. After cooling to room temperature (rt), extract the reaction mixture with DCM and brine and separate the phases. Dry the combined organic layers on MgSO4 and then remove the solvent under reduced pressure. Purify the obtained crude product by recrystallization or column chromatography, and the product I3 It is obtained as a solid.
[1095] synthesis AAV4 General procedure for:
[1096]
[1097] Here X H is a halogen selected from the group consisting of Cl, Br, and I. In a specific embodiment, X H is Cl.
[1098] I3 Bis(pinacolato)diborone (1.00 equivalents), bis(pinacolato)diborone (2.20 equivalents, CAS 73183-34-3), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (0.05 equivalents; CAS: 72287-26-4), and potassium acetate (KOAc; 4.00 equivalents, CAS 127-08-2) are stirred overnight at 100°C under a nitrogen atmosphere in dioxane. After cooling to room temperature (rt), the reaction mixture is extracted with DCM and brine, and the phases are separated. The combined organic layers are dried over MgSO4, and then the solvent is removed under reduced pressure. The obtained crude product is purified by recrystallization or column chromatography, and the product I4 It is obtained as a solid.
[1099] synthesis AAV4 General procedure for:
[1100]
[1101] I4 Sodium peroxide (1.00 equivalents) and sodium periodate (4 equivalents, CAS 7790-28-5) are dissolved in THF / water (4:1 volume ratio) under a nitrogen atmosphere. Hydrochloric acid (2 mol / L, 0.1 equivalents) is added, and the mixture is stirred at room temperature for 24 hours. Consequently, the reaction mixture is extracted with DCM and brine, and the phases are separated. The combined organic layers are dried on MgSO4, and then the solvent is removed under reduced pressure. The obtained crude product is purified by recrystallization or column chromatography, and the product I5 It is obtained as a solid.
[1102] synthesis AAV5 General procedure for:
[1103]
[1104] I5 (1.00 equivalents) is dissolved in chlorobenzene under a nitrogen atmosphere. Boron tribromide (4.00 equivalents, CAS 10294-33-4) is added, and the mixture is stirred at 100°C for 2 hours. After cooling to room temperature (RT), water is added, the resulting solid is filtered, and washed with water and methanol. The obtained crude product is purified by recrystallization or column chromatography, and the product I6 It is obtained as a solid.
[1105] synthesis AAV6 General procedure for:
[1106]
[1107] I6 Dissolve (1.00 equivalents) in chlorobenzene under a nitrogen atmosphere. Add boron trichloride solution (1 M in heptane, 0.67 equivalents, CAS 10294-34-5) at 0°C and stir the mixture at room temperature for 2 hours. Aryl Grignard reagent I6-1 A solution of (e.g., 1 M, 6.00 equivalents in THF) is added to the mixture at 0°C. The reaction mixture is stirred at room temperature for 1 hour. Consequently, the reaction mixture is extracted with DCM and brine, and the phases are separated. The combined organic layers are dried on MgSO4, and then the solvent is removed under reduced pressure. The obtained crude product is purified by recrystallization or column chromatography, and the product P1 It is obtained as a solid.
[1108] cyclic voltammetry
[1109] The cyclic voltammetry is such that the concentration of organic molecules in dichloromethane or a suitable solvent and suitable supporting electrolyte (e.g., 0.1 mol / L tetrabutylammonium hexafluorophosphate) is 10 -3Measurements are taken in a mol / L solution. Measurements are performed at room temperature in a nitrogen atmosphere using a three-electrode assembly (working and counter electrodes: Pt wire, reference electrode: Pt wire), and FeCp2 / FeCp2 is used as an internal standard. + Correction is performed using [the method]. HOMO data was calibrated for the saturated calomel electrode (SCE) using ferrocene as an internal standard.
[1110] Density functional theory calculations
[1111] The molecular structure is optimized using the BP86 functional and Resolution of Identity (RI) approaches. Excitation energies are calculated using the (BP86) optimized structure and employing the Time-Dependent DFT (TD-DFT) method. Orbital and excited state energies are calculated using the B3LYP functional. The Def2-SVP base set and m4-grid for numerical integration are used. The Turbomole program package is used for all calculations.
[1112] Optical physics measurement
[1113] Sample Pretreatment: Spin Coating
[1114] Device: Spin150, SPS euro.
[1115] The sample concentration is 0.2 mg / ml and is dissolved in toluene / DCM.
[1116] Program: 7) 30 seconds at 2000 U / min. After coating, the film is dried at 70°C for 1 minute.
[1117] Fluorescence spectroscopy and phosphorescence spectroscopy
[1118] Horiba’s fluorescence spectrometer “Fluoromax 4P” is used for phosphorescence and photoluminescence analysis.
[1119] μs-range and ns-range time-resolved photoluminescence spectroscopy (FS5)
[1120] Time-resolved photoluminescence (PL) measurements are performed on the Edinburgh Instruments FS5 fluorescence spectrometer. Compared to measurements in the HORIBA setup, better focusing enables an optimized signal-to-noise ratio, making the FS5 system particularly advantageous for measuring transient photoluminescence with delayed fluorescence characteristics. The FS5 consists of a xenon lamp that provides a broad spectrum. The continuous light source is a 150W xenon arc lamp, and selected wavelengths are chosen by a Czerny-Turner monochromator, which is also used to set specific emission wavelengths. The emission from the sample is directed toward a sensitive R928P photomultiplier tube (PMT), which enables the detection of single photons with a peak quantum efficiency of up to 25% over a spectral range between 200 nm and 870 nm. The detector is a temperature-stabilized PMT providing a dark count of less than 300 cps (counts per second). Finally, a tail fit using three exponential functions is applied to determine the transient decay lifetime of delayed fluorescence. Specific lifetime Amplitude corresponding to By assigning weights as,
[1121]
[1122] Delayed fluorescence lifetime This is decided.
[1123] Photoluminescence Quantum Yield Measurement
[1124] The Absolute PL Quantum Yield Measurement C9920-03G system (Hamamatsu Photonics) is used for the measurement of photoluminescence quantum yield (PLQY). Quantum yield and CIE coordinates are determined using software U6039-05 version 3.6.0.
[1125] Maximum emission is expressed in nm, quantum yield Φ in %, and CIE coordinates in x,y values.
[1126] PLQY is determined using the following protocol.
[1127] 1) Quality assurance: Anthracene in ethanol (known concentration) is used as a reference.
[1128] 2) Wavelength: The maximum absorption of the organic molecule is determined, and the molecule is excited using this wavelength.
[1129] 3) Measurement
[1130] Quantum yield is measured for solution or film samples in a nitrogen atmosphere. The yield is calculated using the following equation.
[1131]
[1132] Here, n 광자 represents the number of photons, and Int represents the intensity.
[1133] Fabrication and Characterization of Organic Optoelectronic Devices
[1134] An optoelectronic device, particularly an OLED device, comprising an organic molecule according to the present invention can be manufactured through a vacuum deposition method. If a layer comprises more than one compound, the weight percentage of one or more compounds is expressed in %. Since the total weight percentage value becomes 100%, the fraction of the compound for which no value is specified is equal to the difference between the specified values and 100%.
[1135] An OLED that is not fully optimized is characterized by measuring an external quantum efficiency (%) that depends on intensity and current, calculated using the electroluminescence spectrum and light detected by the photodiode using standard methods. The lifetime of the OLED device is derived from the change in luminance while operating at a constant current density. The LT50 value corresponds to the time when the measured luminance decreases to 50% of the initial luminance, similarly, LT80 corresponds to the time when the measured luminance decreases to 80% of the initial luminance, LT95 corresponds to the time when the measured luminance decreases to 95% of the initial luminance, and so on.
[1136] Accelerated life measurements are performed (e.g., increased current density is applied). For example, 500 cd / m 2 The LT80 value is determined using the following formula.
[1137]
[1138] Here, L0 represents the initial luminance at the applied current density.
[1139] The values correspond to the average of several pixels (typically 2 to 8), and the standard deviation between these pixels is provided.
[1140] HPLC-MS
[1141] HPLC-MS analysis is performed on an Agilent HPLC (1260 series) equipped with an MS detector (Thermo LTQ XL).
[1142] An exemplary typical HPLC method is as follows: Agilent ( Poroshell 120EC-C18, 3.0×100 mm, 2.7 μm HPLC column From ), a reverse-phase column of 3.0 mm × 100 mm and a particle size of 2.7 μm are used for HPLC. HPLC-MS measurements are performed at room temperature (rt) according to the following gradient.
[1143] Flow rate [ml / min] Time [minutes] A[%] B[%] C[%] 1.5 30 40 40 30 1.5 45 10 10 80 1.5 50 40 10 80 1.5 51 30 40 30 1.5 55 30 10 30
[1144] Use the following solvent mixture containing 0.1% formic acid.
[1145] Solvent A: H2O(10%) MeCN(90%) Solvent B: H2O(90%) MeCN(10%) Solvent C: THF(50%) MeCN(50%)
[1146] Take an injection volume of 2 μL for measurement in a solution with a solute concentration of 0.5 mg / ml.
[1147] The ionization of the probe is performed using an atmospheric pressure chemical ionization (APCI) source in positive (APCI+) or negative (APCI-) ionization mode, or by an atmospheric pressure photoionization (APPI) source.
[1148] Example 1
[1149]
[1150] Example 1 is a general synthesis method II and AVV3, AVV4, AVV5 and AVV6 Synthesized by, here (CAS 27973-29-1) as a reactant I2 As, 2-chloro- N -Phenylbenzeneamine (CAS 1205-40-9) as a reactant I2-1 As, and 2,4,6-trimethylphenylmagnesium bromide (1M in THF, CAS 2633-66-1) reactant I6-1 It was used as.
[1151] Additional examples of organic molecules of the present invention
[1152]
[1153]
[1154]
[1155]
[1156]
[1157]
[1158]
[1159]
[1160]
[1161]
Claims
Claim 1 Organic molecule containing the structure of chemical formula Ib: Chemical formula Ib where X is B, Y is N, and R * is selected from the group consisting of independently in each case; hydrogen, deuterium, Me, i Pr, t Bu, SiMe3, SiPh3, and Me, i Pr, t Ph;Z is optionally substituted with one or more substituents independently selected from the group consisting of Bu, and Ph, and is a direct bond; o is an integer of 0 or 1 independently in each case; p is an integer of 0 or 1 independently in each case; m is an integer of 0 or 1 independently in each case; n is an integer of 0 or 1 independently in each case; and R2 is independently selected from the group consisting of: hydrogen, Me, i Pr, t Bu, CN, CF3, Me, i Pr, t Ph, Me, optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph, i Pr, t Pyridinyl, Me, optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph, i Pr, t Carbazolyl, Me, optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3, and Ph, i Pr, t Triazinyl optionally substituted with one or more substituents independently selected from the group consisting of Bu, CN, CF3 and Ph, and N(Ph)2. Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 delete Claim 7 delete Claim 8 In paragraph 1, o is an organic molecule that is 1. Claim 9 A photoelectronic device comprising an organic molecule according to claim 1 as a photoluminescent emitter. Claim 10 In claim 9, the optoelectronic device is an optoelectronic device selected from the group consisting of: · organic light-emitting diode (OLED), · light-emitting electrochemical cell, · OLED sensor, · organic diode, · organic solar cell, · organic transistor, · organic field-effect transistor, · organic laser, and · down-conversion element. Claim 11 (a) one or more organic molecules according to claim 1 in the form of emitter and / or host, and (b) one or more emitter and / or host materials different from the organic molecules of claim 1, and (c) optionally, one or more dyes and / or one or more solvents. Claim 12 An optoelectronic device comprising an organic molecule according to claim 1 or a composition according to claim 11, the optoelectronic device having the form of a device selected from the group consisting of an organic light-emitting diode (OLED), a light-emitting electrochemical cell, an OLED sensor, an organic diode, an organic solar cell, an organic transistor, an organic field-effect transistor, an organic laser, and a down-conversion element. Claim 13 In claim 12, a photoelectronic device comprising - a substrate, - an anode, - a cathode, and - at least one light-emitting layer, wherein the anode or the cathode is disposed on the substrate, and the light-emitting layer is disposed between the anode and the cathode and comprises the organic molecule or the composition. Claim 14 A method for manufacturing a photoelectronic device using an organic molecule according to claim 1 or a composition according to claim 11. Claim 15 A method for manufacturing a photoelectronic device according to claim 14, comprising the step of treating the organic molecule from a solution or by a vacuum evaporation method.
Citation Information
Patent Citations
Blue fluorescent dopant materials and organic thin film and organic light emitting devices comprising the same
CN106654053A
Double-boron fluorescent material, preparation method thereof and OLED (organic light-emitting diode) device
CN108342192A
Condensed ring amine compound and organic electroluminescent element using the same
JP2014205641A
